ASSET PURCHASE AGREEMENT

THIS ASSET PURCHASE AGREEMENT (this "Agreement") is entered into and made effective as of July 24, 2023 (the "Effective Date"), by and between **EPIGENOMICS AG**, a German corporation (the "Seller"), and **NEW DAY DIAGNOSTICS LLC**, a Delaware limited liability company (the "Purchaser").

W I T N E S S E T H:

WHEREAS, Seller is in the business of developing and commercializing patient-friendly blood-based diagnostic tests to detect cancer in multiple indications, including Epi proColon for the detection of colorectal cancer (the "Business"); and

WHEREAS, Seller owns certain intellectual property rights, inventory, and other assets used in the Business; and

WHEREAS, Purchaser desires to acquire, and Seller is willing to sell, the assets owned by Seller primarily used or held for use in the operation of the Business.

NOW, THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants contained herein, and other good and valuable consideration, the receipt, sufficiency, and adequacy of all of which are hereby acknowledged, the parties agree as follows:

1. **Purchase and Sale of Transferred Assets**. Subject to the terms and conditions set forth in this Agreement, at the Closing, Seller shall sell, convey, assign, transfer, and deliver to Purchaser, and Purchaser shall purchase and acquire from Seller, free and clear of Encumbrances (other than Permitted Encumbrances): the Owned Intellectual Property Rights (as defined below and set forth in Schedule 11(f)) and all of Seller's property and assets set forth below, wherever located (but excluding the Excluded Assets, as defined below) (collectively, the "Transferred Assets"):

(a) Inventory. All research-use-only inventory of Seller (to the extent it may be transferred and shipped to Purchaser in compliance with legal and regulatory transfer and shipping Legal Requirements), including the biobanks, in each case with respect to the Business, remaining after the close of business on the Closing Date as further described in the Bill of Sale and Assignment and Assumption Agreement (as defined below) (collectively, the "Inventory");

(b) Seller Agreements. All rights of Seller in, to, and under the agreements listed on Exhibit A (the "Seller Agreements") pursuant to which (i) a license to Intellectual Property Rights primarily related to the Business is granted to Seller or (ii) Seller has granted a license to Owned Intellectual Property Rights to a Third Party; and

(c) Books and Records. All books and records (i) made available to Purchaser in the Data Room and (ii) primarily related to the Owned Intellectual Property Rights, the Inventory and the Seller Agreements (collectively, the "Books and Records").

Notwithstanding anything herein to the contrary, this Agreement will not constitute an assignment or transfer of, an attempted assignment or transfer of, or an agreement to effect an assignment or transfer of any Seller Agreement that is not assignable or transferable without the consent of another Person (and such consent has not been obtained prior to Closing) (the "Non-transferable Assets"), if such assignment or transfer, attempted assignment or transfer, or agreement would constitute a breach of such Seller Agreement in the absence of such consent. To the extent such consent is not obtained prior to Closing, for a period of one hundred eighty (180) days following the Closing Date, Seller will use commercially reasonable efforts to obtain the consent of such other Person to the assignment or transfer of any such Non-transferable Asset to Purchaser in all cases in which such consent is or may be required for such assignment or transfer. Purchaser will reasonably cooperate with Seller in its efforts to obtain such consents. To the extent any such consent cannot be obtained, Seller will use commercially reasonable efforts to provide an alternate reasonable arrangement reasonably satisfactory to Purchaser designed to provide to Purchaser the economic benefits intended to be assigned or transferred to Purchaser under the relevant Non-transferable Asset; provided, however, that Seller shall not be required to (i) undertake any work or take any action that would constitute a breach of any contracts, (ii) modify any of its rights under any Seller Agreements in a manner adverse to Seller, or (iii) incur any Liability, cost or out-of-pocket expense in connection therewith that is not paid by Purchaser; provided, further, that such benefits shall be calculated net of documented out-of-pocket additional costs in connection therewith (including Taxes). Without limiting the generality of the foregoing, the beneficial interest in and to the Seller Agreements, to the fullest extent permitted by the relevant Seller Agreement and applicable Legal Requirements, will pass to Purchaser.

2. **Excluded Assets**. Notwithstanding anything herein to the contrary, all of the right, title, and interest of Seller in and to the following assets, properties, and other rights (the "Excluded Assets") shall be excluded from the Transferred Assets:

(a) All other books and records other than the Books and Records, including but not limited to minute books, incorporation documents, other records having to do with the incorporation of Seller, and any personal information and/or data of, held or maintained by Seller;

(b) All of Seller's cash on hand or on deposit, marketable securities, and other cash equivalents with respect to the Business or otherwise;

(c) All personnel records and other records that Seller is required by Legal Requirements to retain in its possession; provided, however, to the extent permitted by applicable Legal Requirements, Seller shall provide Purchaser with a copy of any such records (other than personnel records) that Purchaser may need in order to conduct the Business;

(d) All (a) trade accounts receivable and other rights to payment from customers of Seller and the full benefit of all security for such accounts or rights to payment, including all trade accounts receivable representing amounts receivable in respect of goods shipped or products sold or services rendered to customers of Seller, (b) all other accounts or

notes receivable of Seller and the full benefit of all security for such accounts or notes, and (c) any claim, remedy or other right related to any of the foregoing;

(e) All rights of Seller under this Agreement, the Bill of Sale and Assignment and Assumption Agreement, the IP Assignment, and all such other documents Seller shall enter into in connection with this Agreement and the transactions contemplated herein (as such terms are defined herein);

(f) All claims for refund of Taxes and other governmental charges of whatever nature as of the Closing Date, and all claims for Tax deposits, Tax credits or Tax attributes (including net operating losses) of Seller; and

(g) All other assets of the Seller, including but not limited to Seller's equity ownership of Subsidiary, the intercompany indebtedness owed by Subsidiary to Seller and the brand name Epigenomics.

3. **Liabilities**. For purposes of this section, "Liabilities" shall mean, with respect to any person or entity, any liability or obligation of such person or entity of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financial statements of such person or entity.

(d) Assumed Liabilities. On the Closing Date, the Purchaser shall assume and agree to discharge only the following Liabilities of the Seller (the "Assumed Liabilities"):

(i) All accounts payable that arise with respect to Inventory and other items that must be ordered in the ordinary course of business, but which will not be delivered to the place of Business until after the Closing Date; and

(ii) Any Liability arising with respect to the operation of the Business and ownership of the Transferred Assets after the Closing.

(e) Retained Liabilities. The Retained Liabilities shall remain the sole responsibility of and shall be retained, paid, performed, and discharged solely by the Seller. "Retained Liabilities" shall mean every Liability of the Seller, other than the Assumed Liabilities, including:

(i) All accounts payable that are due and payable prior to the Closing Date, and accounts payable with respect to Inventory and other items that must be ordered in the ordinary course of business, and which are delivered to the place of Business on or before the Closing Date, even if such Inventory and other items will not be utilized in the Business or sold to customers of the Business until after the Closing Date;

(ii) Any and all payments under any employment agreements, service agreements with consultants or freelancers, employee compensation and incentive plans, benefit (including vacation and severance) plans, programs, policies, and arrangements maintained for the benefit of such employees by the Seller, and any Liability with respect to claims of the Business Employee (as defined below) against the Purchaser arising from the transactions contemplated by this Agreement.

(iii) All Tax Liabilities attributable to taxable periods (or portions thereof) ending before the Closing Date;

(iv) Any Liability arising before Closing under any contracts to which the Seller is a party;

(v) Any Liability to the Seller's customers incurred by the Seller in the ordinary course of business as of the Closing Date including, without limitation, any Liability to the Seller's customers under written warranty agreements;

(vi) Any Liability arising out of or resulting from the Seller's compliance or noncompliance with any Legal Requirement occurring prior to the Closing Date; and

(vii) All Liabilities arising out of, incurred with respect to, or otherwise related to any Excluded Asset, including but not limited to any Liability of either Seller or Epigenomics, Inc. with respect to the intercompany indebtedness between Seller and Epigenomics, Inc.

4. **Consideration Matters**.

(a) The Purchase Price. The purchase price for the Transferred Assets, payable subject to the terms and conditions of Section 4(b), shall be Twelve Million Fifty Thousand and No/100 Dollars ($12,050,000.00) inclusive of cash of Nine Million Eight Hundred Thousand and No/100 Dollars ($9,800,000.00) plus equity in the Purchaser valued at an amount equal to three percent (3%) of the post-merger and subsequent external financing valuation of Purchaser, but in no event valued at less than Two Million Two Hundred Fifty Thousand and No/100 Dollars ($2,250,000.00) (the "Share Consideration") as determined in the most recent external financing round for such entity (collectively, the "Purchase Price"). The Share Consideration shall have the same rights, preferences and privileges, including rights to receive dividends and other distributions, as the equity of Purchaser issued to investors in the last completed financing round for Purchaser, subject to the terms and conditions of the applicable Purchaser investment agreements, copies of which will be provided to Seller as soon as available (the "Purchaser Investment Agreements"). Purchaser shall grant Seller board observer rights pursuant to a board observer rights letter effective as of the issuance of the Share Consideration, with the board observer having the right to attend all meetings of the board of directors of Purchaser, and the right to access all information and materials provided to Purchaser's board of directors, subject to customary carveouts for confidentiality (the "Board Observer Agreement"). For purposes of clarification, the Purchase Price consists of several components, some of which are subject to conditions, including Section 4(b) below).

(b) Elements and Conditions of Payment. Payment of the Purchase Price shall be as follows:

(i) At Closing, Purchaser shall pay to Seller Five Hundred Thousand and No/100 Dollars ($500,000.00) (the "Closing Date Payment") and cause the Share Consideration to be issued to Seller;

(ii) On December 1, 2023, Purchaser shall pay to Seller an amount equal to One Million and No/100 Dollars ($1,000,000.00) (the "Second Tranche Payment"). At or prior to Closing, in order to secure Purchaser's obligation to pay the Second Tranche Payment to Seller on December 1, 2023, Purchaser shall cause to be delivered to Seller the following (the "Second Tranche Payment Agreement"): an escrow agreement between Purchaser and a third party escrow agent acceptable to Seller, pursuant to which Purchaser has caused an amount equal to the Second Tranche Payment to be deposited into an escrow account with the escrow agent, the full amount of which is required by the terms of such escrow agreement to be released to an account designated in writing by Seller by wire transfer on December 1, 2023 without condition, reduction, holdback or offset of any kind and which is otherwise on terms and conditions reasonably acceptable to Seller. On June 30, 2024, Purchaser shall pay to Seller an amount equal to Three Hundred Thousand and No/100 Dollars ($300,000.00). Commencing on March 31, 2024 and on March 31 of each subsequent calendar year, Purchaser shall deliver to Seller a written report, certified in writing by an executive officer of Purchaser (A) describing in reasonable detail the status of the patents and applications relevant for Epi proColon and/or Epi Next-Gen included in the Transferred Assets, as well as the status of Purchaser's and/or its Affiliates', licensees' or sublicensees' activities relating to the milestones set forth in Section 4(b)(iii), and (B) providing a statement of the amount of Net Revenue during the preceding calendar year, and a calculation of the amounts of Epi Next-Gen Earnout payable to Seller in respect thereof pursuant to Section 4(c)(i) and Section 4(c)(ii);

(iii) One Million and No/100 Dollars ($1,000,000.00) will be paid by Purchaser to Seller in the following increments, within five business days after meeting the following milestone events:

A. One Hundred Thousand and No/100 Dollars ($100,000.00) upon the first commercial sale of Epi proColon;

B. Four Hundred Thousand and No/100 Dollars ($400,000.00) upon first reaching Three Million and No/100 Dollars ($3,000,000.00) in Epi proColon sales; and

C. Five Hundred Thousand and No/100 Dollars ($500,000.00) upon first reaching Five Million and No/100 Dollars ($5,000,000.00) in Epi proColon sales.

(iv) One Million and No/100 Dollars ($1,000,000.00) will be paid by Purchaser to Seller within five business days after Epi Next-Gen first receives United States Food and Drug Administration (or any successor agency in the US, "FDA") approval for screening individuals at average risk for colorectal cancer (where average risk is as referenced by FDA at the time of approval);

(v) Two Million and No/100 Dollars ($2,000,000.00) will be paid by Purchaser to Seller within five business days after the Centers for Medicare and Medicaid Services (or any successor agency in the US) agrees to reimbursement for Epi Next-Gen based on FDA approval;

(vi) Four Million and No/100 Dollars ($4,000,000.00) will be paid by Purchaser to Seller in the following increments within five business days after meeting the following Epi Next-Gen sales:

A. Five Hundred Thousand and No/100 Dollars ($500,000.00) upon first reaching Ten Million and No/100 Dollars ($10,000,000.00) in Epi Next-Gen sales;

B. One Million and No/100 Dollars ($1,000,000.00) upon first reaching Twenty Million and No/100 Dollars ($20,000,000.00) in Epi Next-Gen sales; and

C. Two Million Five Hundred Thousand and No/100 Dollars ($2,500,000.00) upon first reaching Fifty Million and No/100 Dollars ($50,000,000.00) in Epi Next-Gen sales.

(c) Earnouts.

(i) In addition to the Purchase Price, Purchaser agrees to pay to Seller an earnout (the "Epi Next-Gen Earnout") on an annual basis, and no later than March 31 of the year following each applicable year as to which Net Revenue (as defined below) occurs as follows:

A. During the period commencing on the date of the first commercial sale of Epi Next-Gen (whether such first commercial sale is prior to or following FDA approval of Epi Next-Gen) and ending on the fourth (4^{th}) anniversary of the first (1^{st}) day of the full month following the earlier of (i) that date on which Net Revenues during a consecutive 12-month period prior to FDA approval equal at least Ten Million and No/100 Dollars ($10,000,000.00), if applicable; or (ii) FDA approval (if Net Revenues in a consecutive 12-month period prior to FDA approval do not equal at least Ten Million and No/100 Dollars ($10,000,000.00)) (such applicable period, the "Initial Earnout Period"), Purchaser shall pay to Seller an earnout equal to five percent (5%) of Net Revenue from sales of Epi Next-Gen;

B. During the two (2) years following the Initial Earnout Period (the "Secondary Earnout Period"), Purchaser shall pay to Seller an earnout equal to three and one half percent (3.5%) of Net Revenue from sales of Epi Next-Gen;

C. Following the Secondary Earnout Period and continuing until the date of the expiration of the last-to-expire of the Valid Claims (as defined below) in respect of the Owned Intellectual Property Rights that claim, cover or are incorporated, in whole or in part, in Epi Next-Gen, Purchaser shall pay to Seller an earnout equal to two and one half percent (2.5%) of Net Revenue from sales of Epi Next-Gen.

D. For purposes of this Section 4(c), "Net Revenue" means the total gross amounts billed or invoiced by Purchaser, and/or any of its Affiliates, and/or any of their respective licensees or sublicensees for sales of Epi Next-Gen to third parties, less any credits for returns actually made as supported by credit memoranda issued to customers, less discounts actually allowed and taken as such by customers and shown on the invoice, less sales taxes, and less shipping and transportation charges actually paid to non-affiliate third parties, as determined from the books and records of such selling party, maintained in accordance with generally accepted accounting principles, consistently applied. Otherwise, no deduction shall be made for direct or indirect costs incurred in manufacturing, selling, advertising, or distributing Epi Next-Gen. "Valid Claim" means a claim of (i) an issued and unexpired patent or a pending patent application that has not been revoked, held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and has not been disclaimed, admitted to be invalid or unenforceable, or (ii) a pending patent application that has not been cancelled, withdrawn, abandoned or rejected by an administrative agency (without the possibility of appeal, reinstatement or re-filing). For clarity, without limiting any other provisions of this Agreement, this definition of "Valid Claim" does not obligate Purchaser to appeal any decision of a court, administrative agency or other governmental agency.

E. Following the Closing, Purchaser shall use commercially reasonable efforts to operate the Business to continue to develop, market and sell Epi proColon and Epi Next-Gen (and Purchaser agrees that the exercise of such commercially reasonable efforts shall include continuing the prosecution and maintenance, and not seeking to invalidate or supporting any Person in any effort to seek to invalidate any, of the patents and patent applications within the Owned Intellectual Property Rights in respect of Epi proColon or Epi Next-Gen). In addition, Purchaser shall use commercially reasonable efforts to (i) demand, receive and collect any and all Net Revenue and all accounts receivable relating to sales of Epi Next-Gen, (ii) institute and prosecute any and all actions Purchaser may deem proper in order to realize such Net Revenue and collect such accounts receivable, and (iii) to do all things reasonably deemed by Purchaser to be

required to realize, recover and collect such Net Revenue and accounts receivable, in each case in the ordinary course of business consistent with Purchaser's revenue and accounts receivable practices with respect to its businesses other than the Business. Seller acknowledges that there is no assurance that Seller will receive any payment in respect of the Epi Next-Gen Earnout and that Purchaser has not promised or projected any such payments.

F. Purchaser shall not, and shall cause its Affiliates not to, sell, assign or otherwise transfer to any Third Party any of the Transferred Assets (other than Inventory) or this Agreement unless the assignee or other transferee expressly agrees in writing to assume the obligations of Purchaser corresponding to such Transferred Assets and the obligations of Purchaser under this Agreement, including those obligations with respect to the payment of the payments pursuant to Sections 4(b) and 4(c) shall apply, *mutatis mutandis*, to such assignee or other transferee. Purchaser shall provide Seller with prompt written notice of any sale, assignment or transfer of this Agreement pursuant to this Section 4(c)(i)(F).

(ii) Purchaser will keep complete, continuous, true and accurate books of accounts and records sufficient to support and verify the calculation of Net Revenue and all Epi Next-Gen Earnout payments payable to Seller under this Agreement for at least two (2) years following the calendar year to which they pertain. Purchaser shall retain and make available such records to an independent, certified public accountant chosen by Seller and reasonably acceptable to Purchaser upon at least 10 days' advance written notice, for inspection during normal business hours, to verify any Epi Next-Gen Earnout payments made under this Agreement. If such accountant provides any audit report to Seller, such accountant shall provide a copy of such audit report to Purchaser at the same time as it provides such report to Seller. Such accountant shall not disclose to Seller any information other than information relating to the accuracy of reports and payments delivered under this Agreement. If Purchaser has conducted previously an audit of such information for the relevant calendar year, Purchaser shall make the results of such audit available to the independent, certified public accountant chosen by Seller and reasonably acceptable to Purchaser. If any audit conducted pursuant to the provisions of this provision shows an underreporting or underpayment of 5% or more in any Epi Next-Gen Earnout payments due to Seller hereunder, Purchaser shall bear the reasonable out-of-pocket costs incurred by Seller in conducting of such audit and shall remit any amounts due to Seller within thirty (30) days of receiving notice thereof from Seller.

(d) Seller's Closing Expenses; Recordation of Transfer and Delivery of Certain Transferred Assets. At the Closing, Seller shall be responsible for paying all of Seller's own costs, expenses, prorations, adjustments, and other amounts contemplated by this Agreement. Purchaser acknowledges and agrees that Purchaser shall be responsible, at its sole cost and expense, for all applicable recordations and perfection of the assignment of the Transferred Assets, including the Owned Intellectual Property Rights included therein, from the titled owner to Purchaser, and that it shall use commercially reasonable efforts to complete the requisite recordation or perfection of such assignments as soon as practicable following the Closing. Purchaser also acknowledges and agrees that all Inventory and other tangible Transferred Assets will be delivered to Purchaser Ex Works (EXW, Incoterms 2020) Seller's or

its designee's facility and, for clarity, Purchaser shall bear and be responsible for all costs and expenses of delivering the tangible Transferred Assets, including all costs of handling, transportation and insurance, and all risk of loss from Seller's or its designee's facility; provided, however, that Seller shall be responsible for any and all costs and expenses associated with moving the Inventory and other tangible Transferred Assets through customs in accordance with the same customs procedures that Seller has followed prior to the date of this Agreement in connection with delivery of inventory to the Subsidiary, as are described in the Data Room.

(e) Allocation of Purchase Price and Epi Next-Gen Earnout. Within 45 days following the Closing, Purchaser shall deliver to Seller a schedule allocating the Purchase Price and Epi Next-Gen Earnout (together with the Assumed Liabilities and all other relevant items required pursuant to Section 1060 of the Code) among the Transferred Assets (the "Allocation Schedule"). The Allocation Schedule will be prepared in accordance with Section 1060 of the Code and the Treasury Regulations thereunder. Neither Purchaser nor Seller shall file any Tax Return, including IRS Form 8594, in a manner that is inconsistent with the foregoing and the Allocation Schedule unless required otherwise pursuant to a "determination" within the meaning of Section 1313(a) of the Code or unless Purchaser and Seller cannot agree on such Allocation Schedule after discussing proposed adjustments made by Seller. Each party shall notify the other party if it receives notice that the IRS or other Governmental Body proposes any allocation different than as set forth in this Section 4(e).

(f) Withholding. Purchaser shall be entitled to deduct and withhold from all amounts payable pursuant to this Agreement all amounts that Purchaser may be required to deduct and withhold under any provision of applicable Legal Requirements. To the extent such amounts are withheld and paid over to the applicable Governmental Body, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. Notwithstanding the above, the parties do not currently intend to deduct or withhold any amount from any payment made hereunder; provided, further, that if it is determined that such withholding is nonetheless required by applicable Legal Requirements (after giving effect to any applicable Tax treaties), the parties agree to use commercially reasonable efforts to cooperate so as to eliminate or reduce any such withholding. The parties shall provide each other with any documentation (including IRS Form W-8 or W-9) reasonably necessary to reduce or eliminate Tax withholding on any payment hereunder. Notwithstanding the foregoing, if Purchaser redomiciles, or assigns, licenses, or sublicenses its rights or obligations under this Agreement, or there is a change of control of Purchaser (each a "Purchaser Tax Action"), and as a result of such Purchaser Tax Action, Purchaser is required to withhold Taxes from or in respect of any amount payable under this Agreement and such Taxes exceed the amount of Taxes that would have been required to be withheld absent such Purchaser Tax Action, the amount payable under this Agreement shall be increased by the amount necessary so that after making all required withholdings (including withholdings on additional amounts payable), Seller receives an amount equal to the sum it would have received had no such Purchaser Tax Action occurred.

5. **Closing**. The consummation of the transactions contemplated in this Agreement shall take place two business days following the satisfaction or waiver of the closing conditions in Section 8 (other than those conditions that by their nature are to be satisfied at the Closing (as

defined below), but subject to the satisfaction or waiver of such conditions) (the "Closing Date"), or at such other time and place as is mutually agreed upon by Purchaser and Seller (the "Closing").

6. **Seller Representative; Tax Matters**.

(a) Seller agrees that Gregory Hamilton will continue to represent the Seller as a consultant until the Closing following the receipt of the requisite approval of Seller's shareholders in accordance with applicable Legal Requirements at a duly noticed shareholders' meeting of Seller to approve the transactions contemplated by this Agreement (the "Required Shareholder Vote"). Seller agrees to use commercially reasonable efforts to solicit the Required Shareholder Vote promptly following the date of this Agreement, subject to applicable Legal Requirements.

(b) Seller and Purchaser shall each be liable for 50% of any stamp, documentary, sales, use, value added, registration, property, excise, transfer or similar Taxes, charges or fees ("Transfer Taxes") that may become payable in connection with the conveyance and transfer of the Transferred Assets to Purchaser or otherwise in connection with the transactions contemplated by this Agreement, and Seller and Purchaser will make all filings, returns, reports and forms as may be required to comply with the provisions of all applicable Legal Requirements relating to Transfer Taxes. Purchaser and Seller will cooperate to the extent reasonably necessary to prepare and file all necessary documents relating to Transfer Taxes as may be required. Each of Purchaser and Seller shall reasonably cooperate with each other to lawfully minimize any Transfer Taxes.

(c) Purchaser, on the one hand, and Seller, on the other hand, shall cooperate fully, as and to the extent reasonably requested by the other party, in connection with the preparation and filing of any Tax Return, statement, report or form, in any audit, litigation or other proceeding with respect to Taxes relating to the Transferred Assets or arising from the transactions contemplated by this Agreement. Such cooperation shall include the retention and (upon the other party's request) the provision of records and information that are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. All real property Taxes, personal property Taxes and similar ad valorem obligations levied with respect to the Transferred Assets for a Straddle Period shall be apportioned between Seller, on the one hand, and Purchaser, on the other hand, as of the Closing based on the number of days of such taxable period ending on the date of the Closing (each such portion of such taxable period, a Pre-Closing Tax Period) and the number of days of such taxable period after the Closing (each such portion of such taxable period, a "Post-Closing Tax Period"). Seller shall be liable for the proportionate amount of such Taxes that is attributable to the Pre-Closing Tax Period, and Purchaser shall be liable for the proportionate amount of such Taxes that is attributable to the Post-Closing Tax Period. Upon receipt of any bill for real or personal property Taxes relating to the Transferred Assets, Seller and Purchaser, as applicable, shall present a statement to the other setting forth the amount of reimbursement to which each is entitled under this Section 6(c) together with such supporting evidence as is reasonably necessary to calculate the proration amount. The proration amount shall be paid by the party

owing it to the other within 20 days after delivery of such statement. In the event that Seller, on the one hand, or Purchaser, on the other hand, shall make any other payment for which it is entitled to reimbursement under this Section 6(c), the other party shall make such reimbursement promptly but in no event later than 20 days after the presentation of a statement setting forth the amount of reimbursement to which the presenting party is entitled along with such supporting evidence as is reasonably necessary to calculate the amount of reimbursement.

7. **Additional Agreements**.

(a) As further inducement for the parties hereunder, Seller and Purchaser agree to execute and/or deliver, or cause to be executed and/or delivered, each of the following:

(i) A Bill of Sale and Assignment and Assumption Agreement, in the form attached hereto as Exhibit B (the " Bill of Sale and Assignment and Assumption Agreement"); and

(ii) An assignment of the Owned Intellectual Property Rights in the form attached hereto as Exhibit C (the "IP Assignment").

(b) Seller agrees that, for three (3) years following the Closing Date, Seller shall not, and shall cause its subsidiaries not to, directly or indirectly, without Purchaser's prior written consent, (i) develop, test, manufacture, distribute, sell or otherwise commercialize any blood-based tests to screen for colorectal cancer (such products, "Competing Products") anywhere in the world, (ii) own or have the right to acquire an interest in, or manage, operate, control or otherwise participate with any Person engaged in the development, testing, manufacture, distribution, sale or other commercialization of any Competing Product anywhere in the world or (iii) otherwise knowingly assist or enable any Third Party to develop, test, manufacture, distribute, sell or otherwise commercialize any Competing Product anywhere in the world (the activities described in this sentence, the "Restricted Business"). Nothing set forth in this Section 7(b) shall prohibit Seller or any of its subsidiaries from (A) being a beneficial owner of less than 5% of the outstanding stock of any publicly traded corporation, or (B) being acquired by a Third Party (including a Third Party that is engaged in the Restricted Business) (for the avoidance of doubt, after such acquisition the restrictions of the first sentence of this Section 7(b) shall not apply with respect to the acquirer or its Affiliates other than Seller and its subsidiaries that existed immediately prior to the acquisition by the Third Party. The parties acknowledge and agree that the temporal limitations set forth in this Section 7(b) are reasonable and necessary to protect legitimate interests of the parties and each agrees not to contest such limitations in any proceeding. The parties acknowledge and agree that the parties would not have entered into this Agreement in the absence of the restrictions set forth in this Section 7(b).

(c) Until the Closing, Seller shall take all reasonable actions to maintain the Owned Intellectual Property Rights and not abandon, cancel, withdraw, disclaim, or admit to be invalid or unenforceable the Owned Intellectual Property Rights, in each case other than the patents and patent applications listed in Schedule 11(f) as "scheduled to be abandoned" and, for clarity, Seller shall have the right to abandon such patents and patent applications prior to the Closing.

8. **Conditions to Closing and Deliverables.** The Closing shall be conditioned upon, and at the Closing the applicable party or parties shall deliver (or cause to be delivered) the following, each of which is incorporated herein by this reference and all of which shall be fully executed as applicable by the parties thereto, on or prior to the Longstop-Date:

(a) (i) The shareholders' meeting of Seller has approved (x) this Agreement pursuant to section 179a of the German Stock Corporation Act (*Aktiengesetz*) and (y) the required amendment(s) of the statutes of Seller, (ii) Seller has provided written notice to Purchaser pursuant to Section 15 confirming (x) that the shareholders' resolutions under clause (i) are in the reasonable view of Seller neither void pursuant to section 241, 243 of the German Stock Corporation Act (*Aktiengesetz*), nor promising nullity actions (*Nichtigkeitsklagen*) have been filed against them, nor can they be successfully challenged void (*angefochten*) or have they been promisingly challenged void (*angefochten*), and (y) that this Agreement can be closed under the German Stock Corporation Act in the reasonable opinion of the executive board of Seller, and (iii) in the reasonable opinion of the executive board of Seller, no promising nullity actions (*Nichtigkeitsklagen*) will be filed up to the time of Closing;

(b) The Closing Date Payment;

(c) The Share Consideration;

(d) Any applicable Purchaser Investment Agreements;

(e) The Board Observer Agreement;

(f) The Bill of Sale and Assignment and Assumption Agreement;

(g) The IP Assignment;

(h) The Second Tranche Payment Agreement;

(i) (x) All of Seller's Fundamental Representations (as hereinafter defined) set forth in Section 11 shall be true and correct in all respects as of the Effective Date and as of the Closing Date, as though made on and as of such dates (except to the extent such representations and warranties are made as of a specified date, such representations and warranties shall be true and correct as of such specified date), and (y) all other representations and warranties of Seller set forth in Section 11 shall be true and correct (in each case, without giving effect to any limitation or qualification as to materiality contained in such representations and warranties) as of the Effective Date and as of the Closing Date, as though made on and as of such dates (except to the extent such representations and warranties are made as of a specified date, such representations and warranties shall be true and correct as of such specified date), except, with respect to this clause (y) only, where the failure of such representations and warranties to be so true and correct does not have, and would not be reasonably expected to have, individually or in the aggregate, a material adverse effect;

(j) Seller shall have performed and complied in all material respects with all of its covenants and obligations under this Agreement required to be performed or complied with by Seller prior to or on the Closing Date; and

(k) Each party shall have delivered to the other party a copy of the resolutions of the board of directors and the shareholders of such party certified by the Secretary or other authorized officer of such party authorizing the transactions contemplated herein, the execution and delivery of all documents required to effectuate such, and designating the officers of such party who are authorized to execute and deliver such documents on behalf of such party, together with a certificate of incumbency with respect to such officers.

9. **Public Announcements**. Unless otherwise required by applicable Legal Requirements or stock exchange requirements, no party to this Agreement shall make any public announcements in respect of this Agreement or the transactions contemplated hereby without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed), and the parties shall cooperate as to the timing and contents of any such announcement.

10. **Representations and Warranties of Purchaser**. In order to induce Seller to enter into this Agreement, Purchaser hereby represents and warrants to Seller that the statements contained in this Section 10 are correct and complete as of the date of this Agreement and will be correct and complete as of the Closing.

(a) Power and Authority. Purchaser is a corporation duly formed, validly existing, and in good standing under the laws of the state of Delaware, and has all requisite power and authority to execute and deliver this Agreement and all other documents or instruments required to be executed and delivered by it by this Agreement, and to carry out the terms of this Agreement and of all such other documents or instruments.

(b) Authorization, etc. This Agreement constitutes legal, valid, binding, and enforceable obligations of Purchaser and its successors and assigns, subject to the effect of bankruptcy, insolvency, reorganization, arrangements, moratorium, and other similar laws now or hereafter in effect, as well as limitations imposed by general principles of equity upon the specific enforceability of any of the remedies, covenants, or other provisions, and the availability of injunctive relief or other equitable remedies.

(c) No Legal Bar. The execution, delivery and performance by the Purchaser of this Agreement and the transactions contemplated hereby do not, and will not: (i) to Purchaser's actual knowledge, breach or contravene any Legal Requirement; (ii) violate any order, judgment, writ, injunction, license, agreement or permit by which Purchaser or its assets or properties may be bound or affected; or (iii) result in or require the creation or the imposition of any Encumbrance on any assets or properties of Purchaser, except as contemplated hereby.

(d) Survival. Each of the representations and warranties made by Purchaser in this Agreement shall be true and correct in all respects when made, shall be true and correct in all

material respects at and as of the Closing as though such representations and warranties were made or given on and as of the Closing, and shall survive the Closing.

(e) No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS SECTION 10 AND IN ANY AGREEMENT REQUIRED HEREUNDER, NEITHER THE PURCHASER NOR ANY OTHER PERSON ACTING ON BEHALF OF THE PURCHASER, INCLUDING ANY OFFICER, DIRECTOR, EMPLOYEE OR REPRESENTATIVE OF THE FOREGOING, MAKES OR HAS MADE ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AT LAW OR IN EQUITY, IN RESPECT OF THE PURCHASER.

11. **Representations and Warranties of Seller.** In order to induce Purchaser to enter into this Agreement, Seller hereby represents and warrants to Purchaser that the statements contained in this Section 11 are correct and complete as of the date of this Agreement and will be correct and complete as of the Closing.

(a) Existence and Good Standing; Power. The Seller is a German corporation duly incorporated, validly existing, and in good standing under the laws of Germany. The Seller has made available to the Purchaser true, correct, and complete copies of the organizational documents of the Seller, each as currently in effect and reflecting any and all amendments thereto through the Closing Date. Such organizational documents are in full force and effect, and Seller is not in violation of any provision thereof. Seller is duly authorized, qualified, or licensed to do business as a foreign entity, and is in good standing, in each of the jurisdictions where it is required to be so qualified. Seller has the requisite corporate power and authority to (i) own, operate, and lease its assets as and where currently owned, operated, and leased, and (ii) carry on the Business as currently conducted.

(b) Title to Tangible Transferred Assets. Seller has good and valid title to, the tangible Transferred Assets, free and clear of all Encumbrances, except for Permitted Encumbrances.

(c) Inventory. All inventory owned by the Seller as of the Closing Date and related to the Business is listed in the Bill of Sale and Assignment and Assumption Agreement. All such inventories are for research use only or otherwise are not intended for commercial sale and/or are not saleable or marketable. ALL INVENTORY IS PROVIDED BY SELLER "AS IS" AND WITHOUT WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, TITLE OR FITNESS FOR A PARTICULAR PURPOSE. SELLER MAKES NO REPRESENTATION OR WARRANTY THAT ANY INVENTORY WAS MANUFACTURED IN ACCORDANCE WITH LAW AND SELLER SHALL HAVE NO LIABILITY TO PURCHASER, ITS AFFILIATES, LICENSEES, SUBLICENSEES OR ANY OTHER THIRD PARTY ARISING OUT OF OR RELATED TO THE INVENTORY, AND ALL USE OF INVENTORY AND ANY DATA OR MATERIALS GENERATED USING ANY INVENTORY IS AT SUCH PERSONS' SOLE RISK.

(d) Compliance with Legal Requirements. Except as set forth in Schedule 11(d), the Seller is, and has been in the past five (5) years, in compliance in all material respects

with all Legal Requirements applicable to the Seller with respect to its operation of the Business and the Transferred Assets or by which any Transferred Asset is bound.

(e) Litigation. There are no complaints, actions, suits, proceedings, hearings, investigations, or audits (collectively, an "Action") pending or, to the Seller's knowledge, threatened against or by, related to or affecting the Business, or the Transferred Assets. To the knowledge of Seller, no event has occurred, or circumstances exist, that could give rise to or serve as a basis for the commencement of any Action against, related to, or affecting the Business, or the Transferred Assets.

(f) Intellectual Property Rights. Schedule 11(f) sets forth, with details regarding the registered owner, registration, and application numbers and dates indicated, as applicable, and in the case of unregistered trademarks, a complete and correct list of all of the following intellectual property rights owned by the Seller: (i) patents and patent applications and (ii) registered copyrights and applications therefor, registered trademarks, material unregistered trademarks, and applications for registration of trademarks (the "Owned Intellectual Property Rights"). All of the Owned Intellectual Property Rights used by the Seller primarily in the conduct of the Business or otherwise in its possession are owned solely by the Seller and the Seller has the exclusive right to use and possess such Owned Intellectual Property Rights for the life thereof for any purpose, free from (i) any liens and (ii) any requirement of any past, present or future royalty payments, license fees, charges, or other payments or conditions or restrictions whatsoever, except in each case of clauses (i) and (ii) any Permitted Encumbrance. Except (A) for licenses and rights granted in any Seller Agreement and (B) limited rights granted in any nondisclosure agreements or service provider agreements entered into by Seller in the ordinary course of business, the Seller has not licensed or otherwise granted any right to any Person under any Owned Intellectual Property Rights, nor has the Seller otherwise agreed not to assert any such Owned Intellectual Property Rights against any Person.

To the knowledge of the Seller, (i) the operation of the Business as currently conducted, or any part thereof, including the manufacture, use, sale, and importation of products of the Seller and the possession, use, disclosure, copying, or distribution of any information, data, products, or other tangible or intangible Intellectual Property Rights in the possession of the Seller primarily related to the Business, and (ii) the possession or use of the Owned Intellectual Property Rights as currently used has not and does not infringe, dilute, violate or otherwise conflict with any intellectual property right of any other Person. To the Seller's knowledge, none of the Owned Intellectual Property Rights of the Seller is being infringed or otherwise is used or available for use by any Person other than the Seller, except for use permitted in any Seller Agreement or in any nondisclosure agreements or service provider agreements entered into by Seller in the ordinary course of business. To the Seller's knowledge, no person is infringing, misappropriating, or otherwise violating the Owned Intellectual Property Rights in any material respect.

(g) Conduct of Business. Since the date of the Seller's last publicly filed financial statements on March 31, 2023, the Business and operations of the Seller with respect to the Business have been conducted in the ordinary course of business and there has not occurred any material adverse change or event that, with notice, lapse of time or both, would reasonably

be expected to result in a material adverse change in the operation of the Business or the Transferred Assets.

(h) Brokers. No Person has acted directly or indirectly as a broker, finder, or financial advisor for the Seller in connection with the negotiations relating to the transactions contemplated by this Agreement for which the Purchaser or the Seller will become obligated to pay a fee or commission.

(i) Product Warranty; Product Liability. Each product manufactured, designed, sold, leased, licensed, repaired or delivered by Seller in the operation of the Business is and has been in conformity with the specifications under which the product is normally and has normally been manufactured and all applicable Legal Requirements, and all express warranties, and to the knowledge of Seller, Seller is not subject to any Action and does not have any Liability (and there is no basis for any present or future Action against any of them giving rise to any Liability) for replacement or repair of or damages in connection with its products, except as disclosed to Purchaser in writing. No product manufactured, designed, sold, leased, licensed, repaired or delivered by Seller in the operation of the Business is subject to any guaranty, warranty, or other indemnity beyond the applicable standard terms and conditions of sale, lease, or license that have been provided to Purchaser prior to the date hereof, Seller is not subject to any Action and does not have any Liability (and there is no basis for any present or future Action against Seller giving rise to any Liability) arising out of any injury to individuals or property as a result of the ownership, possession, sale, distribution or use of any product manufactured, designed, sold, leased, licensed, repaired or delivered by Seller in the operation of the Business.

(j) Financial Statements. Seller's consolidated balance sheets and the related profit and loss statements, and cash flows statements for the fiscal year ended December 31, 2022 and for the three-month period ended March 31, 2023 (collectively, the "Financial Statements") are publicly available. The Financial Statements are accurate and complete and present fairly, in all material respects, the financial position, results of operations, retained earnings, and cash flows of the Seller at the dates and for the time periods indicated, and have been prepared in accordance with IFRS and applicable supplemental German Legal Requirements, and reviewed by the management of the Seller.

(k) Right to Purchase. Seller has not granted to any Person any option or other agreement of any kind whereby any Person other than Purchaser will have acquired or will have any right to acquire title to all or any portion of the Transferred Assets.

(l) Related Party Transactions. Except as set forth in Schedule 11(l), there is not any (i) contract or other arrangement primarily related to the Business, (ii) any interest in any contract or any material tangible or intangible asset that is used by Seller in the conduct of the Business, or is necessary for or incidental to the conduct of the Business, or (iii) any indebtedness to or from Seller, in the case of clauses (i), (ii) and (iii), between Seller, on the one hand, and any Related Party of Seller, on the other hand (such contracts and arrangements, collectively, the "Related Party Transactions"). For purposes of this section, "Related Party" means any affiliate, officer or director of Seller, (ii) any spouse, former spouse, child, parent, parent of a spouse, sibling, grandchild or grandparent of any of the persons listed in clause (i) above, (iii) any affiliate of any of the persons listed in clause (i) or (ii) above, (iv) any

corporation or organization of which such person listed in clause (i) or (ii) above is an officer or partner or otherwise controls such person, and (v) any trust or other estate in which any of the persons listed in clause (i) or (ii) above has a substantial beneficial interest or as to which such person serves as trustee or in a similar fiduciary capacity.

(m) OFAC/AML/Patriot Act.

i. Seller is not a person with whom a United States citizen, entity organized under the laws of the United States or its territories or entity having its principal place of business within the United States or any of its territories (collectively, a "U.S. Person"), is prohibited from transacting business of the type contemplated by this Agreement, whether such prohibition arises under United States law, regulation, executive orders and lists published by the Office of Foreign Assets Control, Department of the Treasury ("OFAC") (including those executive orders and lists published by OFAC with respect to Persons that have been designated by executive order or by the sanction regulations of OFAC as Persons with whom U.S. Persons may not transact business or must limit their interactions to types approved by OFAC ("Specially Designated Nationals and Blocked Persons")) or other applicable Legal Requirements. Neither Seller nor, to Seller's actual knowledge, any person who owns an interest in Seller (other than the owner of publicly traded shares) (collectively, a "Seller Party") is now nor shall be at any time prior to or at the Closing a person with whom a U.S. Person, including a United States Financial Institution as defined in 31 U.S.C. 5312, as periodically amended ("Financial Institution"), is prohibited from transacting business of the type contemplated by this Agreement, whether such prohibition arises under United States law, regulation, executive orders and lists published by OFAC (including those executive orders and lists published by OFAC with respect to Specially Designated Nationals and Blocked Persons) or other applicable Legal Requirements.

ii. Neither Seller nor, to Seller's actual knowledge, any Seller Party: (A) is under investigation by any Governmental Body for, or has been charged with, or convicted of, money laundering, drug trafficking, terrorist related activities, violation of the U.S. Foreign Corrupt Practices Act of 1977, as amended, and all other applicable Legal Requirements relating to anti-bribery and anti-corruption, sanctions, money laundering, anti-terrorism and export/import controls, any crimes which in the United States would be predicate crimes to money laundering, or any violation of any Anti-Money Laundering Laws; (B) has been assessed civil or criminal penalties under any Anti-Money Laundering Laws; or (C) has had any of its funds seized or forfeited in any action under any Anti-Money Laundering Laws. For purposes of this section, "Anti-Money Laundering Laws" shall mean laws and sanctions, state and federal, criminal and civil, that: (w) limit the use of and/or seek the forfeiture of proceeds from illegal transactions; (x) limit commercial transactions with designated countries or individuals believed to be terrorists, narcotics dealers or otherwise engaged in activities contrary to the interests of the United States; (y) require identification and documentation of the parties with whom a Financial Institution conducts business; or (z) are designed to disrupt the flow of funds to terrorist organizations. Such laws and sanctions shall be deemed to include the USA PATRIOT Act of 2001, Pub. L. No. 107-56 (the "Patriot Act"), the Bank Secrecy Act, 31 U.S.C. Section 5311 et. seq., the Trading with the Enemy Act, 50

U.S.C. App. Section 1 et. seq., the International Emergency Economic Powers Act, 50 U.S.C. Section 1701 et. seq., and the sanction regulations promulgated pursuant thereto by OFAC, as well as Laws relating to prevention and detection of money laundering in 18 U.S.C. Sections 1956 and 1957.

iii. Seller is in compliance with any and all applicable provisions of the Patriot Act.

(n) Employment. Except for one employee who belongs to the Business and whose employment ends on or about October 31, 2023 (the "Business Employee"), assuming the Closing occurs on or before such date, as of the Closing, there are no employees, consultants, freelancers, temporary workers, leased employees or any other service provider with an economically similar role which belong to the Business and have a claim to transfer their employment or other contractual relationship to Purchaser or transfers to Purchaser by operation of law as a result of the consummation of the transaction contemplated by this Agreement.

(o) Knowledge. For purposes of this Agreement, "Seller's knowledge" or "Seller's actual knowledge" means the actual knowledge of Jens Ravens.

(p) No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES OF SELLER CONTAINED IN THIS SECTION 11, NEITHER THE SELLER NOR ANY OTHER PERSON ACTING ON BEHALF OF THE SELLER, INCLUDING ANY OFFICER, DIRECTOR, EMPLOYEE OR REPRESENTATIVE OF THE SELLER, MAKES OR HAS MADE ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AT LAW OR IN EQUITY, IN RESPECT OF THE SELLER.

12. **Indemnification**.

(a) Indemnification by Purchaser. Purchaser hereby agrees to indemnify, defend, and hold harmless Seller Indemnitees from and against any and all Damages, whether or not involving a third-party claim, asserted against, resulting to, imposed upon, or incurred by a Seller Indemnitee, directly or indirectly, by reason of or resulting from any of the following:

(i) The inaccuracy or breach of any representation or warranty of Purchaser contained in or made pursuant to this Agreement (regardless of whether such breach is deemed "material");

(ii) The breach of any covenant of Purchaser contained in this Agreement;

(iii) Any Tax Liability (including interest, penalties, assessments, or similar charges) incurred in connection with the operation of the Business after the Closing Date; or

(iv) The Assumed Liabilities, and any and all Damages arising from or related to the Transferred Assets, the Business, or activities of Purchaser after the Closing Date.

(b) Indemnification by Seller. Seller hereby agrees to indemnify, defend, and hold harmless Purchaser Indemnitees from and against any and all Damages, whether or not involving a third-party claim, asserted against, resulting to, imposed upon, or incurred by a Purchaser Indemnitee, directly or indirectly, by reason of or resulting from any of the following:

(i) The inaccuracy or breach of any representation or warranty of Seller contained in or made pursuant to this Agreement (regardless of whether such breach is deemed "material");

(ii) The breach of any covenant of Seller contained in this Agreement;

(iii) Any Tax Liability (including interest, penalties, assessments, or similar charges) incurred in connection with the operation of the Business on or prior to the Closing Date; or

(iv) The Retained Liabilities, and any and all Damages arising from or related to the Transferred Assets, the Business, or activities of Seller on or prior to the Closing Date.

(c) Survival of Representations and Warranties; Certain Limitations.

(i) An Indemnitee's right to recover Damages for breaches of the representations and warranties of Seller or Purchaser contained in this Agreement, as applicable, the disclosure schedules attached hereto, if any, or any agreement, or any certificate or instrument delivered by or on behalf of either party to the other party pursuant to this Agreement or in connection with the transactions contemplated herein shall survive the consummation of the transactions contemplated herein and shall continue in full force and effect for a period of eighteen (18) months from the Closing Date ("Survival Period"); except that (x) Seller's representations and warranties contained in Section 11(a) (Existence and Good Standing; Power), Section 11(c) (Title to Tangible Transferred Assets), Section 11(h) (Brokers), and any representation or warranty breach as a result of Fraud, shall survive until the claims in respect thereof would be barred by the respective applicable statute of limitations, and (y) Purchaser's representations and warranties contained in Section 10(a) (Power and Authority), Section 10(b) (Authorization, etc.), and Section 10(c) (No Legal Bar), and any representation or warranty breach as a result of Fraud, shall survive until the claims in respect thereof would be barred by the respective applicable statute of limitations (the representations and warranties listed in (x) and (y) above being the "Fundamental Representations"). Anything to the contrary notwithstanding, the Survival Period shall be extended automatically to include any time period necessary to resolve a written claim for indemnification which was made in reasonable detail before expiration of the Survival Period but not resolved prior to its expiration, and any such extension shall apply only as

to the claims so asserted and not so resolved within the Survival Period. Liability for any such item shall continue until such claim shall have been finally settled, decided, or adjudicated.

(ii) Subject to the last sentence of this Section 12(c)(ii), an indemnifying party shall not be required to make any indemnification payment pursuant to Section 12(c)(i) until such time as the total amount of all Damages that have been directly or indirectly suffered or incurred by an Indemnitee, or to which an Indemnitee has otherwise directly or indirectly become subject, exceeds $10,000 (the "Deductible") in the aggregate. Once the total amount of such Damages incurred by an Indemnitee exceeds the Deductible, then the Indemnitee shall be entitled to be indemnified, held harmless against, compensated and reimbursed for that portion of such Damages exceeding the Deductible. Notwithstanding the foregoing, the limitations set forth in this clause (ii) shall not apply to Damages based upon, arising out of, with respect to or by reason of (i) any inaccuracy or breach of any Fundamental Representations or (ii) any representation or warranty breached as a result of Fraud. Except in the case of Fraud, the aggregate amount of all Damages for which Seller shall be liable (i) pursuant to Section 12(b)(i) (other than Fundamental Representations) shall not exceed $1,400,000 and (ii) pursuant to Section 12(b)(ii) and Section 12(b)(iii) shall not exceed cash amounts actually received by Seller, up to an aggregate amount of $9,800,000.

(d) Indemnification Claims.

(i) If any Indemnitee has incurred or suffered or claims to have incurred or suffered, or believes that it may incur or suffer, Damages for which it is or may be entitled to be held harmless, indemnified, compensated or reimbursed under this Section 12, such Indemnitee may deliver a notice to the Indemnifying Party (any such notice being referred to as a "Notice of Indemnification Claim," and the claim for indemnification, compensation and reimbursement described in such Notice of Indemnification Claim being referred to as an "indemnification claim"), which shall (i) state that such Indemnitee believes that that there is or has been an inaccuracy in or breach of a representation, warranty, covenant or obligation contained in this Agreement or that such Indemnitee is otherwise entitled to be held harmless, indemnified, compensated or reimbursed under this Section 12, (ii) contain a description of the circumstances supporting such Indemnitee's belief that there is or has been such an inaccuracy or breach or that such Indemnitee may otherwise be entitled to be held harmless, indemnified, compensated or reimbursed and (iii) contain a good faith, non-binding, preliminary estimate of the aggregate dollar amount of actual and potential Damages that have arisen and may arise as a result of the inaccuracy, breach or other matter referred to in such notice (the aggregate amount of such estimate, as it may be modified by such Indemnitee in good faith from time to time, being referred to as the "Claimed Amount").

(ii) During the 20-day period commencing upon the delivery by an Indemnitee to the Representative of a Notice of Indemnification Claim (the "Dispute Period"), the Indemnifying Party shall deliver to the Indemnitee a written response (the "Response Notice") in which the Indemnifying Party: (i) agrees that the full Claimed

Amount is owed to the Indemnitee; (ii) agrees that part (but not all) of the Claimed Amount is owed to the Indemnitee (such amount as is agreed to be owed the "Agreed Amount"); or (iii) asserts that no part of the Claimed Amount is owed to the Indemnitee. Any part of the Claimed Amount that is not agreed by the Indemnifying Party to be owed to the Indemnitee pursuant to the Response Notice (or the entire Claimed Amount, if the Indemnifying Party asserts in the Response Notice that no part of the Claimed Amount is owed to the Indemnitee) shall be referred to as the "Contested Amount" (it being understood that the Contested Amount shall be modified from time to time to reflect any good faith and reasonable modifications by the Indemnitee to the Claimed Amount). If there is a Contested Amount, the Indemnifying Party and the Indemnitee shall attempt in good faith to resolve the dispute related to the Contested Amount. If the Indemnitee and the Indemnifying Party resolve such dispute in writing, then their resolution of such dispute shall be binding on the Indemnifying Party, Seller, Purchaser and the other Indemnitees and a settlement agreement stipulating the amount owed to the Indemnitee (the "Stipulated Amount") shall be signed by the Indemnitee and the Indemnifying Party.

(iii) If the Indemnifying Party and the Indemnitee are unable to resolve the dispute relating to any Contested Amount during the 30-day period commencing upon the delivery of the Response Notice, then either the Indemnitee or the Indemnifying Party may submit the contested portion of the indemnification claim to court in accordance with Section 20. The final award setting forth the aggregate amount owed to the Indemnitee shall be referred to as the "Award Amount".

(e) Additional Indemnification Provisions. For purposes of determining (i) whether any breach of any representation or warranty contained in this Agreement has occurred or whether any such representation or warranty was inaccurate, and (ii) the amount of Damages subject to indemnification resulting from such breach or inaccuracy, any qualifications or exceptions contained in such representation or warranty relating to "material", "materially", "materiality", "material adverse effect", or other qualification based on materiality, shall be disregarded. Each party hereto acknowledges and agrees that the representations and warranties in this Agreement are the product of negotiations among the parties and represent an agreed upon contractual allocation of risk among the parties. Each party shall be entitled to rely upon, and shall be deemed to have relied upon, all of the representations, warranties, covenants and agreements of each other party set forth herein.

(f) Satisfaction of Indemnification Claims. If Seller does not pay any Agreed Amount, Stipulated Amount or Award Amount owed by Seller under this Section 12 to Purchaser within thirty (30) days of such amount being determined, then Purchaser shall have the right to withhold an amount equal to the amount of such Agreed Amount, Stipulated Amount or Award Amount (but not in excess of such amount) from the following, and in the following order (and subject to all of the other limitations set forth in this Section 12): (i) first, if the $300,000.00 portion of the Purchase Price due and payable to Seller on June 30, 2024 has not yet been paid to Seller, by reducing such amount to the extent of the unpaid amount of such Agreed Amount, Stipulated Amount or Award Amount; (ii) second, if any portion of the Epi Next-Gen Earnout is then due and payable, by reducing the amount of the then payable portion of Epi Next-Gen Earnout by the unpaid amount of such Agreed Amount, Stipulated Amount or Award

Amount; (iii) third, if any consideration is then distributable in respect of the Share Consideration, by reducing the amount of such consideration by the unpaid amount of such Agreed Amount, Stipulated Amount or Award Amount; and (iv) fourth, by reduction on its stock/membership interest ledger of that number of shares/membership interest of the Share Consideration as is equal to the amount of such Agreed Amount, Stipulated Amount or Award Amount divided by the then fair market value per share/membership unit of the Share Consideration at the time of the payment. To the extent any Agreed Amount, Stipulated Amount, or Award Amount owed by Seller under this Section 12 is not paid or otherwise satisfied as provided in the preceding sentence, such amount shall bear interest at the Applicable Rate or, if less, the maximum rate permitted by applicable Legal Requirement, and Seller shall reimburse Purchaser for any and all costs or expenses of any nature or kind whatsoever (including reasonable legal fees) incurred in seeking to collect such amount, and no limitation in this Section 12 shall apply to any such interest or reimbursement. In each case, the exercise of such right to reduce or set off shall not constitute a breach of any Purchaser obligations under this Agreement, and the exercise or failure to exercise such right to reduce or set off shall not constitute an election of remedies or limit Purchaser in any manner in the enforcement of any other remedies that may be available to Purchaser. For purposes of this Section 12, "Damages" shall be net of any insurance recoveries actually paid to an Indemnitee under any insurance policy in connection with the facts giving rise to the right of indemnification. For the avoidance of doubt, no amounts will be deducted or withheld of offset from the Second Tranche Payment (including, for clarity, from the Second Tranche Payment Agreement) pursuant to this Section 12 or otherwise.

(g) Exclusivity. Following the Closing, except for (i) Fraud, (ii) specific performance or injunctive or other equitable relief, (iii) a breach of this Section 12, the indemnities and other sources of recourse provided for in this Section 12 shall be the exclusive remedies of the parties and their respective representatives, successors and permitted assigns for any breach of or inaccuracy in any representation or warranty made by the parties in this Agreement, or any breach, non-fulfillment or default in the performance of any of the covenants or agreements contained in this Agreement.

(h) Adjustments to Purchase Price. All indemnification and other payments under this Agreement shall, to the extent permitted by applicable Legal Requirements, by treated for all income Tax purposes as adjustments to the Purchase Price.

13. **Further Assurances**. From time to time following the Closing, each of the parties shall execute and deliver, or cause to be executed and delivered, such further certificates, agreements, instruments of conveyance, and other documents, and take such other actions as the other party may reasonably request or as may be necessary or appropriate, to consummate or implement the transactions contemplated by this Agreement or to evidence such events or matters. The Purchaser shall cooperate in all reasonable respects with any audit of the Seller, including by providing all information, reports and documentation, reasonable assistance, access to systems and participating in any conversations with auditors regarding same.

14. **Termination**. This Agreement may be terminated only by (i) the mutual consent of Seller and Purchaser, (ii) either Seller or Purchaser, if the shareholders' meeting of Seller has not approved (x) this Agreement pursuant to section 179a of the German Stock Corporation Act (*Aktiengesetz*) or (y) the required amendment(s) of the statutes of the Seller, in each case on or before October 31, 2023. Notwithstanding the foregoing, this Agreement may be terminated by either Seller or Purchaser if the Closing has not occurred by the Longstop-Date; provided, however, that neither party shall be permitted to terminate this Agreement if the failure to consummate the Closing is primarily attributable to a failure on the part of such party to perform any covenant in this Agreement required to be performed by such party at or prior to the Closing.

15. **Notices.** Any notice or other communication required or permitted to be given pursuant to this Agreement or by applicable Legal Requirements shall be in writing and shall be deemed received (a) on the date delivered, if delivered in person to the person or department specified below, (b) three (3) business days after depositing the same in the U.S. Mail, certified or registered, with return receipt requested, or (c) one (1) business day following the date deposited with FedEx or other national overnight carrier, and in each case addressed as follows:

If to Purchaser to:

New Day Diagnostics LLC
6701 Baum Drive, Suite 110
Knoxville, Tennessee 37919
Attention: Eric Mayer, President and CEO

With a copy to (which shall not constitute notice hereunder):

Brock Shipe Klenk PLC
265 Brookview Centre Way, Suite 604
Knoxville, Tennessee 37919
Attention: John G. Brock
Email: jbrock@bskplc.com

If to Seller to:

Epigenomics AG
Bertha-Benz-Str. 5
10557 Berlin
Germany
Attention: Jens Ravens, Vorstand/Executive
Email: jens.ravens@epigenomics.com

With a copy to (which shall not constitute notice hereunder):

Cooley LLP
10264 Science Center Drive
San Diego, CA 92121-1117

Attention: Ken Rollins
Email: krollins@cooley.com

Any party may change its address to another single address by notice given as herein provided, except that any change of address must be actually received in order to be effective.

16. **Brokerage.** The parties agree that no brokerage fee is owed and that no broker is involved or in any way connected with the sale of the Transferred Assets provided for herein or with respect to the transactions contemplated hereby.

17. **Assignability**. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties hereto and their respective successors and assigns; provided, however, that except as permitted under Section 4(c)(i)(F), neither this Agreement, nor any of the rights hereunder may be assigned (whether by merger, consolidation, sale or otherwise) by Seller (prior to the Closing) or Purchaser without the prior written consent of the other party, and any attempted assignment of this Agreement or any of such rights without such consent shall be void and of no effect.

18. **Expenses**. Each party shall pay its own costs and expenses incurred with respect to the negotiation, execution and delivery of this Agreement.

19. **Further Assurances**. The parties agree that at any time, and from time to time, after execution and delivery of this Agreement, they shall, upon the request of any other party, execute and deliver such further documents and do such further things as such other party may reasonably request in connection with and in furtherance of this Agreement.

20. **Governing Law; Venue; WAIVER OF JURY TRIAL**. This Agreement shall be governed by and interpreted in accordance with the substantive, internal laws of the State of Delaware without giving effect to conflict of laws principles thereof. If there is a lawsuit, the parties agree to submit to the jurisdiction of, and exclusive venue in, the state and federal courts of the State of Delaware. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

21. **Captions**. The section headings are inserted only for the purpose of convenient reference and the parties acknowledge that such headings may not adequately or accurately describe the contents of the sections which they head. Such headings shall not be deemed to govern, limit, modify, or in any other manner affect the scope, meaning, or intent of the provisions of this Agreement or any part or portion thereof, nor shall they otherwise be given any legal effect.

22. **Entire Agreement**. This Agreement and the Confidentiality Agreements contain the entire agreement between the parties hereto with respect to the transactions contemplated by this Agreement and supersede all prior written or unwritten arrangements or understandings with respect thereto. All parties represent that they are not relying on any representation, statement, or

action by any other party except as expressly stated herein. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, heirs, beneficiaries, fiduciaries, personal representatives, and executors.

23. **Counterparts**. This Agreement may be signed by each of the parties in one or more counterparts, each of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument. The parties agree that in proving this Agreement in any legal proceeding it shall only be necessary for a party to produce a fully executed copy of this Agreement executed in counterparts, which shall be deemed admissible into evidence in any subsequent litigation between two or more of the parties without the necessity of authentication of any signature or accounting for or producing any original.

24. **Third Party Beneficiaries**. Except as provided in Section 12, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto), any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

25. **Severability**. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable Legal Requirements, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

26. **No Amendment**. This Agreement may not be modified, amended, or revoked, except in a writing signed by all parties.

27. **Opportunity to Consult with Counsel**. Each party has been advised to seek separate and independent counsel in connection with the review, execution, and delivery of this Agreement. The parties acknowledge and stipulate that, to the extent a conflict of interest exists between them, Brock Shipe Klenk PLC has only represented the Purchaser in connection with the negotiation of the terms and conditions of this Agreement and Cooley LLP has only represented the Seller in connection with the negotiation of the terms and conditions of this Agreement. The parties acknowledge and agree that, in deciding to execute this Agreement, they have relied on their own judgment and the advice of legal counsel, and that they have had the opportunity to consult, and have consulted, with legal, financial, and other personal advisors of their own choosing as they have deemed appropriate, in assessing whether to execute this Agreement. As such, this Agreement shall not be construed more strictly against any party, but shall instead be construed evenly as to both parties.

28. **Bulk Sales Laws**. The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar Legal Requirements of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Transferred Assets to the Purchaser; it being understood that any Liabilities arising out of the failure of Seller to comply with the requirements and provisions of any bulk sales, bulk transfer or similar Legal Requirements of any jurisdiction which would not otherwise constitute Assumed Liabilities shall be treated as Excluded Liabilities.

29. **Certain Definitions**.

Applicable Rate. "Applicable Rate" means the prime rate of interest reported from time to time by *The Wall Street Journal* plus six percent (6%) per annum.

Affiliate. "Affiliate" when used with respect to any specified Person, shall mean any other Person who or that, directly or indirectly through one or more intermediaries, Controls, is Controlled by or is under common Control with such specified Person.

Code. "Code" shall mean the Internal Revenue Code of 1986, as amended.

Confidentiality Agreements. "Confidentiality Agreements" shall mean, collectively, (i) the Confidentiality and Nondisclosure Agreement dated effective March 6, 2023 by and between Seller and Purchaser, as the same may be amended from time to time and (ii) the Confidential Disclosure and Standstill Agreement dated effective March 6, 2023 by and between Seller and Purchaser, as the same may be amended from time to time.

Control. "Control" shall mean, as to any Person, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise. The term "**Controlled**" shall have a correlative meaning.

Damages. "Damages" shall mean liabilities, damages, Taxes, payments, obligations, losses, costs and expenses (including reasonable out-of-pocket attorneys' fees, court costs, expert witness fees, transcript costs and other expenses of litigation), settlements, awards and judgments (at law or in equity) of any nature, but shall not include consequential, unforeseeable or punitive damages unless such damages are part of any judgment or award against an Indemnitee in actions by third parties.

Data Room. "Data Room" shall mean the online data room utilized for the transactions contemplated hereby or delivered directly to a representative of Purchaser at least one business days prior to the date of this Agreement (and, for clarity, documents included in such data room or so delivered directly to a representative of Purchaser for inclusion in the Data Room shall be considered "made available", "furnished", "delivered" or "provided" by Seller for purposes of this Agreement).

Encumbrance. "Encumbrance" shall mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).

Entity. "Entity" shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust,

company (including any limited liability company or joint stock company), firm or other enterprise, association, organization or entity.

Epi Next-Gen. "Epi Next-Gen" shall mean any assay for average risk screening for colon cancer that incorporates any of the Owned Intellectual Property Rights, other than Epi proColon.

Epi proColon. "Epi proColon" shall mean the FDA-approved blood test for colorectal cancer screening.

Fraud. "Fraud" shall mean common law fraud (with scienter) under the Delaware General Corporation Law in the making of the representations and warranties (a) in Section 11 (in the case of Seller) and (b) in Section 10 (in the case of Purchaser).

Governmental Body. "Governmental Body" shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, instrumentality, official, organization, unit, body or Entity and any court or other tribunal); or (d) self-regulatory organization.

IFRS. "IFRS" shall mean International Financial Reporting Standards as applicable in the European Union

Indemnitee. "Indemnitee" shall mean, as applicable, a Seller Indemnitee or a Purchaser Indemnitee.

Intellectual Property Rights. "Intellectual Property Rights" shall mean and include all rights in or to intellectual property of the following types, which may exist or be created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, and mask works; (b) trademark and trade name rights and similar rights; (c) trade secret rights; (d) patents and industrial property rights; and (e) all registrations, renewals, extensions, continuations, divisions, or reissues of, and applications for, any of the rights referred to in clauses (a) through (d) above.

IRS. "IRS" shall mean the United States Internal Revenue Service.

Legal Requirement. "Legal Requirement" shall mean any federal, state, local, municipal, foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, order, award, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body.

Longstop-Date. "Longstop-Date" shall mean December 31, 2023.

Permitted Encumbrances. "Permitted Encumbrances" shall mean: (a) liens for Taxes that are not yet due and payable; (b) liens imposed by law and incurred in the ordinary course of business for obligations not yet due and payable; (c) liens in respect of pledges or deposits under

workers' compensation laws or similar legislation; and (d) in the case of Intellectual Property Rights within the Transferred Assets, the terms and restrictions set forth in any Seller Agreement.

Person. "Person" shall mean any individual, Entity or Governmental Body.

Pre-Closing Tax Period. "Pre-Closing Tax Period" shall mean any taxable year or period that ends on or before the Closing Date and, with respect to any Straddle Period, the portion of such taxable year or period ending on the Closing Date.

Purchaser Indemnitees. "Purchaser Indemnitees" shall mean (a) Purchaser; (b) Purchaser's current and future Affiliates; (c) the respective Representatives of the Persons referred to in clauses "(a)" and "(b)" above; and (d) the respective successors and assigns of the Persons referred to in clauses "(a)", "(b)" and "(c)" above.

Representatives. "Representatives" shall mean officers, directors, employees, partners, agents, attorneys, accountants, advisors and representatives.

Seller Indemnitees. "Seller Indemnitees" shall mean (a) Seller; (b) Seller's current and future Affiliates; (c) the respective Representatives of the Persons referred to in clauses "(a)" and "(b)" above; and (d) the respective successors and assigns of the Persons referred to in clauses "(a)", "(b)" and "(c)" above.

Straddle Period. "Straddle Period" shall mean any taxable that begins on or before but does not end on the Closing Date.

Subsidiary. "Subsidiary" shall mean Epigenomics, Inc., a Delaware corporation and wholly owned subsidiary of Seller.

Tax. "Tax" shall mean any federal, state, local, or non-U.S. tax of any kind whatsoever including income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, escheat, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax, including any interest, penalty, or addition thereto, whether disputed or not and including any obligations to indemnify or otherwise assume or succeed to the Tax liability of any other Person.

Tax Return. "Tax Return" shall mean any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

Third Party. "Third Party" shall mean any Person other than Seller, Purchaser or an Affiliate of Seller or Purchaser.

[*Remainder of page intentionally left blank; signatures on following page*]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement, intending to be legally bound, on the date first above written.

PURCHASER:

New Day Diagnostics LLC, a Delaware limited liability company

By: Eric Mayer
_____
Name: Eric Mayer
Title: President and Chief Executive Officer

SELLER:

Epigenomics AG, a German corporation

By: _____
By: Jens Ravens
Title: Vorstand/Executive

IN WITNESS WHEREOF, the parties hereto have executed this Agreement, intending to be legally bound, on the date first above written.

PURCHASER:

New Day Diagnostics LLC, a Delaware limited liability company

By: _____
Name: Eric Mayer
Title: President and Chief Executive Officer

SELLER:

Epigenomics AG, a German corporation

By: _____
By: Jens Ravens
Title: Vorstand/Executive

EXHIBIT A

SELLER AGREEMENTS

1. Non-Exclusive License Agreement dated as of February 19, 2008 by and between Seller and Quest Diagnostics, Incorporated.

2. Non-Exclusive License Agreement dated as of February 17, 2009 by and between Seller and Quest Diagnostics, Incorporated.

3. Patent Assignment and License Agreement dated as of December 14, 2015 by and between Seller and Therawis Diagnostics GmbH.

EXHIBIT B

BILL OF SALE AND ASSIGNMENT AND ASSUMPTION AGREEMENT

[Attached]

BILL OF SALE AND ASSIGNMENT AND ASSUMPTION AGREEMENT

THIS BILL OF SALE AND ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Agreement") is made as of _____, 2023, by and between **EPIGENOMICS AG**, a German corporation ("Seller"), and **NEW DAY DIAGNOSTICS LLC**, a Delaware limited liability company ("Purchaser" and with Seller, each a "Party" and, together, the "Parties").

RECITALS

WHEREAS, Seller and Purchaser are parties to that certain Asset Purchase Agreement dated as of July 24, 2023 (the "Purchase Agreement");

WHEREAS, pursuant to Section 1 of the Purchase Agreement, Seller has agreed to sell, convey, assign, transfer and deliver to Purchaser, free and clear of all Encumbrances (other than Permitted Encumbrances), and Purchaser has agreed to purchase and accept, all of the right, title and interest of Seller in, to and under the Transferred Assets;

WHEREAS, pursuant to the Purchase Agreement, Purchaser has agreed to assume, pay, perform and discharge the Assumed Liabilities; and

WHEREAS, Seller and Purchaser desire to document, and set forth the terms of, the sale, conveyance, assignment, transfer and delivery of the Transferred Assets, and the assumption of the Assumed Liabilities.

NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements in the Purchase Agreement, the Parties agree as follows:

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows:

1. Definitions. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Purchase Agreement.

2. Assignment of Transferred Assets. Effective as of the date of this Agreement, Seller hereby irrevocably sells, conveys, assigns, transfers and delivers to Purchaser free and clear of Encumbrances (other than Permitted Encumbrances), all of Seller's right, title and interest, as of the Closing, in and to the Transferred Assets, including the biobank material described on Exhibit A and the research use only inventory described on Exhibit B, and Purchaser hereby accepts such sale, conveyance, assignment, transfer and delivery.

3. Assignment of Seller Agreements. Effective as of the date of this Agreement, Seller hereby assigns, conveys and transfers to Purchaser all right, title and interest into and the Seller Agreements and Purchaser hereby accepts such assignment, conveyance and transfer, and Purchaser pursuant to Section 4 below assumes all Liabilities of Seller under the Seller Agreements to the extent

arising out of obligations which were otherwise to have been performed or required to be performed by Seller under the Seller Agreements after the date of this Agreement.

4. Assumption. Effective as of the date of this Agreement, Purchaser hereby assumes and agrees to pay, perform and discharge when due, in accordance with and pursuant to the terms of the Purchase Agreement, all of the Assumed Liabilities. The foregoing expressly excludes, and nothing herein shall be deemed to convey to Purchaser, the Retained Liabilities.

5. Third Parties. The assumption by Purchaser of certain obligations of Seller as provided in Section 4 of this Agreement is not intended by the Parties to expand the rights or remedies of any third party against Purchaser or Seller, as the case may be, as compared to the rights and remedies which such third party would have had against Seller had Purchaser not consummated the transactions contemplated by the Purchase Agreement. Nothing contained herein will, or should be construed to, prejudice the right of Purchaser or Seller, as the case may be, to contest any claim or demand with respect to any litigation or liability assumed or not assumed, respectively, hereunder; and Purchaser or Seller, as the case may be, will have all rights which Seller has or may have to defend or contest any such claim or demand.

6. Terms of the Purchase Agreement. The terms of the Purchase Agreement are incorporated herein by reference. This Agreement is made in accordance with and is subject to all the terms, representations, warranties, covenants, agreements and limitations set forth in the Purchase Agreement and such terms, representations, warranties, covenants, agreements and limitations contained in the Purchase Agreement shall not be superseded or deemed enlarged, modified or altered in any way hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict between the terms of this Agreement and the Purchase Agreement, the Purchase Agreement shall control.

7. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[*Signature Pages Follow*.]

IN WITNESS WHEREOF, Seller and Purchaser have executed and delivered this Agreement as of the date first written above.

SELLER:

EPIGENOMICS AG

By: _____
Name: Jens Ravens
Title: Vorstand/Executive

IN WITNESS WHEREOF, Seller and Purchaser have executed and delivered this Agreement as of the date first written above.

PURCHASER:

NEW DAY DIAGNOSTICS LLC

By: _____
Name: Eric Mayer
Title: President and Chief Executive Officer

Exhibit A

Biobank Tube Counts

Study Number	Study Name	Final Count	Data Room Count	Explanation
1	PRESEPT	11043	11043	• n/a
2	RUSH 2022	1540	n/a	• n/a
3	RUSH 2018	883	883	• n/a
4	ECS-0001	650	646	• An additional four (4) samples were identified at the biobank during the final inventory audit.
5	SPR0012	249	255	• Unable to cross reference six (6) samples against clinical manifest.
6	ECS-0002	111	111	• n/a

Exhibit B

Research Use Only Materials

Epigenomics Stock 07/ 2023

Article Description	REF	LOT	Expiration Date	Quantity
Plasma Quick Kit - RUO	M5-02-001	2202673	9/30/2023	172
Lysis Binding Buffer- RUO	37089D	1306196	7/25/2022	409
Wash a Concentrate - RUO	37088D	1306192	7/25/2022	409
Wash a Concentrate - RUO	M5-02-001	2012019-W	12/7/2022	419
Lysis Binding Buffer- RUO	M5-02-001	2012023L	12/7/2022	419
Control Kit - RUO	M5-02-003	2202682	9/30/2024	225
Sensitive PCR Kit- RUO	M5-02-002	2202679	7/31/2024	74

EXHIBIT C

INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT

[Attached]

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

THIS INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this "***Assignment***"), dated as of [ ], 2023, is entered into by and between Epigenomics AG, a German corporation (the "***Assignor***"), and New Day Diagnostics LLC, a Delaware limited liability company (the "***Assignee***"). Capitalized terms used but not otherwise defined in this Assignment shall have the meanings assigned to them in the Purchase Agreement (as defined below).

WHEREAS, Assignor and Assignee are each parties to that certain Asset Purchase Agreement dated as of July 24, 2023 (the "***Purchase Agreement***"), pursuant to which, among other things, Assignor has agreed to assign to Assignee all of its rights, title and interests in the patents, patent applications and trademarks described on Exhibit A attached hereto (collectively, the "***Intellectual Property Assets***").

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Assignment. Assignor hereby sells, assigns, and transfers to Assignee and Assignee's successors, assigns and permitted designees, all of the Intellectual Property Assets, and all claims and rights in and to all income, royalties, damages, claims, and payments now or hereafter due or payable with respect to all or any of the foregoing, and in and to all causes of action, either in law or in equity, for past, present or future infringement, misappropriation, violation, dilution, unfair competition or other unauthorized use or conduct in derogation or violation of or based on any of the foregoing rights, and the right to receive all proceeds and damages therefrom. Assignee hereby accepts such sale, assignment, and transfer.

2. Recordation. Assignor hereby authorizes the Commissioner of Patents and the Commissioner for Trademarks of the United States Patent and Trademark Office, and the officials of corresponding entities or agencies in any applicable jurisdictions outside the United States to record and register this Assignment upon request by Assignee.

3. Terms of the Purchase Agreement. The terms of the Purchase Agreement, including, but not limited to, the representations, warranties, covenants, agreements, and indemnities relating to the Intellectual Property Assets are incorporated herein by this reference. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

4. Governing Law. This Assignment shall be governed by and interpreted in accordance with the substantive, internal laws of the State of Delaware without giving effect to conflict of law principles thereof.

5. Counterparts. This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

6. Binding Effect. This Assignment shall be binding upon and shall inure to the benefit of the parties and their representatives, successors, and assigns.

[Signature Page to Follow]

IN WITNESS WHEREOF, the parties have executed this Intellectual Property Assignment Agreement to be effective as of the date first above written.

ASSIGNEE:

New Day Diagnostics LLC, a Delaware limited liability company

By: _____
Name: Eric Mayer
Title: President and Chief Executive Officer

ASSIGNOR:

Epigenomics AG, a German corporation

By: _____
By: Jens Ravens
Title: Vorstand/Executive

EXHIBIT A

INTELLECTUAL PROPERTY ASSETS

Patents and Patent Applications

Patent Title	Registered Owner	Country	Application Number /Patent Number	Filing Date /Grant Date	Status
VERFAHREN ZUR BESTIMMUNG DES METHYLIERUNGSGRADES VON BESTIMMTEN CYTOSINEN IN GENOMISCHER DNA IM SEQUENZKONTEXT 5'-CPG-3'	Epigenomics AG	US	9,719,131	01.08.2017	[redacted]
Highly sensitive method for the detection of cytosine methylation patterns	Epigenomics AG	US	7,229,759	12.06.2007	[redacted]
METHOD AND NUCLEIC ACIDS FOR THE ANALYSIS OF COLON CELL PROLIFERATIVE DISORDERS	Epigenomics AG	US	9,988,683	05.06.2018	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	DE	111 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	ES	111 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	FR	1 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	GB	1 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	IT	1 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	US	9,863,001	09.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	IT	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	FR	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	ES	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	DE	2354248	03.01.2018	[redacted]
Methods and nucleic acids for	Epigenomics AG	CH	2354248	03.01.2018	[redacted]

analyses of colorectal cell proliferative disorders					[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	GB	2354248	03.01.2018	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	CH	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	GB	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	FR	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	CH	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	DE	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	ES	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	IT	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	DE	60 2005 044 492.0	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	ES	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	FR	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	GB	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	IT	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	US	8,679,745	25.03.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	US	8,962,246	24.02.2015	[redacted]
Method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	US	7,700,282	20.04.2010	[redacted]
Method for the carry-over protection in DNA amplification systems targeting methylation analysis	Epigenomics AG	US	8,753,810	17.06.2014	[redacted]

achieved by a modified pre-treatment of nucleic acids					
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	ES	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	3269826	11.03.2020	[redacted]
METHOD FOR THE CALIBRATION AND VERIFICATION OF METHYLATION ANALYSIS METHODS WITH THE AID OF NON-METHYLATED DNA	Epigenomics AG	DE	1 711 628	04.11.2009	[redacted]
METHOD FOR THE CALIBRATION AND VERIFICATION OF METHYLATION ANALYSIS METHODS WITH THE AID OF NON-METHYLATED DNA	Epigenomics AG	FR	1 711 628	04.11.2009	[redacted]
METHOD FOR THE CALIBRATION AND VERIFICATION OF METHYLATION ANALYSIS METHODS WITH THE AID OF NON-METHYLATED DNA	Epigenomics AG	GB	1 711 628	04.11.2009	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	CH	1 869 215	07.05.2014	[redacted]

IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	FR	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	DE	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	ES	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	CH	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	IT	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	GB	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	EP	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	DE	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	ES	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	FR	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	GB	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	IT	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	US	8,129,107	06.03.2012	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	US	8,586,302	19.11.2013	[redacted]
Method for quantification of methylated DNA	Epigenomics AG	US	8,703,414	22.04.2014	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	AT	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	AU	2005293703	03.06.2010	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	BE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	CA	2,581,500	12.02.2013	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis	Epigenomics AG	CH	1 659 186	21.05.2008	[redacted]

achieved by a modified pre-treatment of nucleic acids					
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	DK	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	DE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	ES	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	FR	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	GB	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	IE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	IT	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	JP	4727670	22.04.2011	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	LU	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	NL	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	PT	1 659 186	21.05.2008	[redacted]

A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	SE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	TR	1 659 186	21.05.2008	[redacted]
METHOD FOR THE DETERMINATION OF THE DNA METHYLATION LEVEL OF A CPG POSITION IN IDENTICAL CELLS WITHIN A TISSUE SAMPLE	Epigenomics AG	US	8,912,129	16.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	AE	933/2007	17.04.2006	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	AU	2006236620	08.06.2012	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	BR	PI0607508-8	12.01.2021	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CA	2,606,296	21.05.2019	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	ZL200680012490.0	14.05.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	ZL201410147754.X	28.07.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HK	HK1202137	22.06.2018	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	ZL 2017 1 0510986.0	18.03.2022	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HK	HK1250521	23.12.2022	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	202210279361.9	17.04.2006	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	RU	13634	30.06.2010	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	EG	1102/2007	17.04.2006	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ES	2 045 335	31.12.2014	[redacted]

Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	FR	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CH	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	DE	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	GB	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IT	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	EP	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HK	HK1118868	18.02.2015	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ID	P000038296	17.04.2015	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IL	186556	29.08.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IN	248746	19.08.2011	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	JP	5341506	16.08.2013	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	JP	5808306	18.09.2015	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	KR	10-1708544	14.02.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	MX	290670	03.10.2011	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	PH	1-2007-502117	06.01.2012	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SG	183708	14.08.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	7,951,563	31.05.2011	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	8,900,829	02.12.2014	[redacted]

Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ZA	2007/08701	26.11.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	AT	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	BE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CH	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CZ	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	DK	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	EP	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	DE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ES	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	FI	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	FR	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	GB	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	GR	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HU	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IT	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	LU	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	NL	1 721 992	08.10.2008	[redacted]

Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	PL	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	PT	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SI	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SK	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	TR	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	7,749,702	06.07.2010	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	9,695,478	04.07.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	10,385,402	20.08.2019	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	11,186,879	30.11.2021	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	17/512,833	17.04.2006	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	AU	2006236363	14.02.2013	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	CA	2,603,815	26.09.2017	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	EP	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	AT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	BE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	BG	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	CH	1 871 912	29.02.2012	[redacted]

Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	CY	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	CZ	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	DE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	DK	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	EE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	ES	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	FI	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	FR	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	GB	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	GR	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	HU	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	IE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	IS	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	IT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	LT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	LU	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	LV	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	MC	1 871 912	29.02.2012	[redacted]

Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	NL	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	PL	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	PT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	RO	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	SE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	SI	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	SK	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	TR	1 871 912	29.02.2012	[redacted]
A Method For Providing DNAFragments Derived From A Remote Sample	Epigenomics AG	JP	5674696	09.01.2015	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	JP	5133238	16.11.2012	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	US	10,731,215	04.08.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	AU	2007237444	05.09.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CA	2,649,777	14.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	EP	2 479 283	22.06.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	5323680	26.07.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	US	17/590,200	17.04.2007	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	CH	2 049 684	06.05.2015	[redacted]

A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	GB	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	DE	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	IT	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	ES	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	FR	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	EP	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	US	8,771,939	08.07.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	EP	2044221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	EP	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2 634 265	14.09.2016	[redacted]

METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	US	16/143,085	23.07.2007	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	EP	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	IT	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	GB	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	FR	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	ES	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	DE	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	CH	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	DE	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	ES	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	GB	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	FR	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	EP	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	CH	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	IT	2 099 938	16.11.2016	[redacted]

Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	JP	5562034	20.06.2014	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	JP	6017497	07.10.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	US	9,605,306	28.03.2017	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	US	9,850,532	26.12.2017	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	CH	2 044 215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	EP	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	DE	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	ES	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	FR	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	GB	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	IT	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	US	9,939,441	10.04.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	AU	2008207110	30.01.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CA	2,675,895	22.03.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CA	2,921,557	08.02.2022	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	RU	018010	30.04.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2 258 871	14.05.2014	[redacted]

METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	BE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	SE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CZ	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GR	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	HR	P20140692	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	HU	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	EE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DK	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FI	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	AT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	PL	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	MC	2 258 871	14.05.2014	[redacted]

METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	MT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IS	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	NL	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	NO	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	SI	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	SK	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	TR	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	LT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	LU	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	LV	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	PT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	RO	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	BG	2 258 871	14.05.2014	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	CH	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	DE	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	ES	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	FR	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	GB	2 115 165	14.03.2012	[redacted]

Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	IT	2 115 165	14.03.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IL	199894	01.03.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IL	233548	31.10.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	5342456	16.08.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	5818374	09.10.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	GB	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	FR	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	CH	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	DE	1 842 926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	ES	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	IT	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	EP	1 842 926	19.08.2015	[redacted]
IMPROVED METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	WO	PCT/EP2022/072276	08.08.2022	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL	Epigenomics AG	ES	3078751	01.08.2018	[redacted]

PROLIFERATIVE DISORDERS					
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	EP	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF LUNG CARCINOMA	Epigenomics AG	JP	5694776	13.02.2015	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	ES	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CH	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	GB	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	EP	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FI	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	GR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CY	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CZ	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SI	2 479 289	06.04.2016	[redacted]

METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SK	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	TR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	RO	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HU	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IS	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LU	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LV	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	MC	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	MT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NL	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NO	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	PL	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	PT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	AT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	BE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	BG	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	EE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DK	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HK	HK1172656	23.06.2017	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	GB	3101141	16.10.2019	[redacted]

METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	EP	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IT	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FR	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CH	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	ES	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HK	1231931	04.12.2020	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HU	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IS	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LT	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LU	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LV	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	MC	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NL	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NO	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SI	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FI	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	BE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DK	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HR	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION	Epigenomics AG	US	8,623,599	07.01.2014	[redacted]

ANALYSIS					
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	6013910	30.09.2016	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	CH	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	EP	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	DE	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	ES	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	FR	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	GB	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	IT	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	US	9,624,530	18.04.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	AU	2012282528	28.07.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	BR	1120140004439	23.03.2021	[redacted]

METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	CA	2,840,149	26.10.2021	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	CN	201810020458.1	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	RU	034232	20.01.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IT	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	GB	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	FR	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	ES	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	DE	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	EP	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	CH	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	DK	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	FI	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	HR	P20180001	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	HU	2729579	04.10.2017	[redacted]

METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IE	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	AL	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IS	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	NL	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	NO	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	LT	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	LU	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	LV	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	MC	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	MK	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	SE	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	SI	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	ID	IPD000047814	14.09.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IL	230303	01.09.2018	[redacted]

METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IN	36/DELNP/2014	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	JP	6397762	07.09.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	KR	10-2046668	13.11.2019	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	MX	358117	06.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	HK	1197754	27.07.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	PH	1-2014-500063	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	SG	196421	24.10.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	US	10,626,462	21.04.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	US	11,261,499	01.03.2022	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	US	17/577,836	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	ZA	2014/00089	30.03.2022	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	CH	1 963 352	08.09.2010	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	CN	101331148	27.06.2012	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	DE	1 963 352	08.09.2010	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	FR	1 963 352	08.09.2010	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	GB	1 963 352	08.09.2010	[redacted]

NEW METHOD FOR BISULFITE TREATMENT	Epigenomics AG	JP	5374679	04.10.2013	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	US	8,137,937	20.03.2012	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	CN	ZL 201580068711.5	26.03.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IT	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	GB	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	FR	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	ES	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	DE	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	CH	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	EP	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	NL	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	NO	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	SE	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	SI	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	AL	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	DK	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	FI	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	HR	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR	Epigenomics AG	HU	3234184	20.03.2019	[redacted]

DIAGNOSING CANCER					abandoned
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IE	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IS	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	LT	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	LU	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	LV	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	MC	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	MK	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	HK	1245845	24.04.2020	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IT	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	GB	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	FR	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	ES	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	CH	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	DE	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	EP	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	HK	HK40014441	14.04.2022	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	JP	6731942	09.07.2020	[redacted]
METHODS FOR DETECTING CpG	Epigenomics AG	US	9,957,575	01.05.2018	[redacted]

METHYLATION AND FOR DIAGNOSING CANCER					
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	US	11,345,966	31.05.2022	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	US	17/730,100	18.12.2015	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	CN	201780009085.1	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	JP	7261587	12.04.2023	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	JP	2022-211507	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	US	16/072,792	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	EP	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HK	42021042786.0	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	IT	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	EP	20214665.0	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	CH	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	DE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	ES	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	FR	3408407	06.01.2021	[redacted]

METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	GB	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	MT	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	FI	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	AL	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	DK	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HR	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HU	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	IE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	IS	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	LT	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	LU	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	LV	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	MC	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	MK	3408407	06.01.2021	[redacted]

METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	NL	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	SE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	SI	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	BE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	NO	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HK	HK40000100	15.10.2021	[redacted]
METHODS FOR DETECTING HEAD AND NECK CANCER	Epigenomics AG	CN	202080028396.4	13.02.2020	[redacted]
METHYLATED GENOMIC DNA AS A MARKER OF HEAD AND NECK CANCER	Epigenomics AG	HK	62022054573.0	13.02.2020	[redacted]
METHYLATED GENOMIC DNA AS A MARKER OF HEAD AND NECK CANCER	Epigenomics AG	EP	20704032.0	13.02.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	AU	2020406068	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	CA	3,161,720	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	CN	202080095046.X	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	EP	20829901.6	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	JP	JP2022-536776	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	MX	MX/a/2022/007434	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	US	17/785,302	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	WO	PCT/EP2020/086498	16.12.2020	[redacted]
METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	EP	21742157.7	21.07.2021	[redacted]
METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	JP	JP2023-504199	21.07.2021	[redacted]

METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	US	18/015,912	21.07.2021	[redacted]
METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	WO	PCT/EP2021/070362	21.07.2021	[redacted]
IMPROVED METHODS FOR DETECTING CANCER FIELD OF THE INVENTION	Epigenomics AG	EP	22199681.2	04.10.2022	[redacted]
MULTI-ANALYTE DIAGNOSTIC AND PROGNOSTIC ASSAYS FOR COLORECTAL CANCER AND USES THEREOF	Epigenomics AG	US	63/381,706	31.10.2022	[redacted]
MULTI-ANALYTE DIAGNOSTIC AND PROGNOSTIC ASSAYS FOR COLORECTAL CANCER AND USES THEREOF	Epigenomics AG	US	63/413,043	04.10.2022	[redacted]

Trademarks

Country	Trademark Application Number /Registration Number	Mark	Status	Owner
DE	304 59 611	HeavyMethyl	Registered	Epigenomics AG
GB	UK00800888748	HeavyMethyl	Registered	Epigenomics AG
CN	200612567	HeavyMethyl	Registered	Epigenomics AG
WO	0 888 748	HeavyMethyl	Registered	Epigenomics AG
EM	0888748	HeavyMethyl	Registered	Epigenomics AG
AR	2906270	Epi proColon	Registered	Epigenomics AG
BR	907685650	Epi proColon	Registered	Epigenomics AG
BR	907685331	Epi proColon	Registered	Epigenomics AG
BR	907685722	Epi proColon	Registered	Epigenomics AG
CN	13532351	Epi proColon	Registered	Epigenomics AG
CL	1183742	Epi proColon	Registered	Epigenomics AG
CL	1164785	Epi proColon	Registered	Epigenomics AG
CN	13532350	Epi proColon	Registered	Epigenomics AG
CN	13532352	Epi proColon	Registered	Epigenomics AG
CL	1175380	Epi proColon	Registered	Epigenomics AG
RU	564091	Epi proColon	Registered	Epigenomics AG
AR	2820458	Epi proColon	Registered	Epigenomics AG
AR	2820457	Epi proColon	Registered	Epigenomics AG
DE	30 2009 031 560	Epi proColon	Registered	Epigenomics AG
EM	008 703 654	Epi proColon	Registered	Epigenomics AG
GB	UK00908703654	Epi proColon	Registered	Epigenomics AG
US	4,235,996	Epi proColon	Registered	Epigenomics AG
CN	13532349	Epi proLung	Registered	Epigenomics AG
CN	13532347	Epi proLung	Registered	Epigenomics AG
CN	13532348	Epi proLung	Registered	Epigenomics AG
DE	30 2009 031 561	Epi proLung	Registered	Epigenomics AG
EM	008 703 671	Epi proLung	Registered	Epigenomics AG
GB	UK00908703671	Epi proLung	Registered	Epigenomics AG
DE	30 2009 031 562	Epi proProstate	Registered	Epigenomics AG
EM	008 703 662	Epi proProstate	Registered	Epigenomics AG
GB	UK00908703662	Epi proProstate	Registered	Epigenomics AG
EM	008 794 505	Epi proBladder	Registered	Epigenomics AG
GB	UK00908794505	Epi proBladder	Registered	Epigenomics AG
DE	30 2009 039 312	Epi proBreast	Registered	Epigenomics AG

EM	008 794 521	Epi proBreast	Registered	Epigenomics AG
GB	UK00908794521	Epi proBreast	Registered	Epigenomics AG
DE	30 2010 002 554	Epi proCervix	Registered	Epigenomics AG
EM	009 234 477	Epi proCervix	Registered	Epigenomics AG
GB	UK00909234477	Epi proCervix	Registered	Epigenomics AG
EM	017950053	HCCBloodTest (Bildmarke)	Registered	Epigenomics AG
US	5,935,705	HCCBloodTest	Registered	Epigenomics AG
GB	UK00917950053	HCCBloodTest (Bildmarke)	Registered	Epigenomics AG
US	6,126,563	HCCBloodTest	Registered	Epigenomics AG

SCHEDULE 11(d)

With notice dated April 7, 2014, Epigenomics AG ("**Epigenomics**") received an investment grant by the Investitionsbank Berlin ("**IBB**") under the joint scheme for improving regional economic structures. Over the following years, the grant was amended several times (by notices dated December 14, 2016, June 22, 2017 and November 28, 2017) and the finally granted amount of EUR 428.500,00 was paid out to Epigenomics in several installments between 2015 and 2017.

The investment grant was tied to the fulfillment of several conditions. In particular, Epigenomics was obliged to create a certain number of additional permanent jobs and keep the augmented number of jobs for five years after the grant period was concluded (i.e., until April 2022). Due to various economic, personal, and regulatory circumstances that were not under Epigenomics AG's control, Epigenomic was unable to keep the required workforce over the relevant time.

After Epigenomics had notified the IBB that not all jobs could be kept for the required grant period, IBB announced by letter dated September 9, 2022 its intention to revoke the investment grant plus interest in its entirety. In its reply dated October 6, 2022 Epigenomics laid out the legal arguments, why the grant should not be revoked. Nonetheless, with notice dated November 21, 2022, the IBB revoked the investment grant and requested repayment of EUR 428.500.00 plus 5 percentage points interest since April 2019 by 19 December 2022.

After evaluating the legal prospects of an appeal, Epigenomics decided not to file an appeal and repaid the full amount in December 2022. To date, no further payments in the context of this investment grant are outstanding.

SCHEDULE 11(f)

[Attached]

Schedule 11(f)
Owned Intellectual Property Rights

Patents and Patent Applications

Patent Title	Registered Owner	Country	Application Number /Patent Number	Filing Date /Grant Date	Status
VERFAHREN ZUR BESTIMMUNG DES METHYLIERUNGSGRADES VON BESTIMMTEN CYTOSINEN IN GENOMISCHER DNA IM SEQUENZKONTEXT 5'-CPG-3'	Epigenomics AG	US	9,719,131	01.08.2017	[redacted]
Highly sensitive method for the detection of cytosine methylation patterns	Epigenomics AG	US	7,229,759	12.06.2007	[redacted]
METHOD AND NUCLEIC ACIDS FOR THE ANALYSIS OF COLON CELL PROLIFERATIVE DISORDERS	Epigenomics AG	US	9,988,683	05.06.2018	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	DE	111 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	ES	111 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	FR	1 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	GB	1 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	IT	1 654 388	27.06.2007	[redacted]
VERFAHREN ZUM NACHWEIS VON CYTOSIN-METHYLIERUNGEN IN DNA	Epigenomics AG	US	9,863,001	09.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	IT	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	FR	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	ES	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	DE	2354248	03.01.2018	[redacted]
Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	CH	2354248	03.01.2018	[redacted]

Methods and nucleic acids for analyses of colorectal cell proliferative disorders	Epigenomics AG	GB	2354248	03.01.2018	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	CH	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	GB	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	FR	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	CH	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	DE	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	ES	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	IT	3342877	29.01.2020	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	DE	60 2005 044 492.0	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	ES	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	FR	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	GB	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	IT	1 794 319	13.08.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	US	8,679,745	25.03.2014	[redacted]
METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM AN ARCHIVED SAMPLE	Epigenomics AG	US	8,962,246	24.02.2015	[redacted]
Method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	US	7,700,282	20.04.2010	[redacted]
Method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	US	8,753,810	17.06.2014	[redacted]

METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	ES	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	3269826	11.03.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	3269826	11.03.2020	[redacted]
METHOD FOR THE CALIBRATION AND VERIFICATION OF METHYLATION ANALYSIS METHODS WITH THE AID OF NON-METHYLATED DNA	Epigenomics AG	DE	1 711 628	04.11.2009	[redacted]
METHOD FOR THE CALIBRATION AND VERIFICATION OF METHYLATION ANALYSIS METHODS WITH THE AID OF NON-METHYLATED DNA	Epigenomics AG	FR	1 711 628	04.11.2009	[redacted]
METHOD FOR THE CALIBRATION AND VERIFICATION OF METHYLATION ANALYSIS METHODS WITH THE AID OF NON-METHYLATED DNA	Epigenomics AG	GB	1 711 628	04.11.2009	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	CH	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE	Epigenomics AG	FR	2803734	20.09.2017	[redacted]

CONVERSION OF DNA					
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	DE	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	ES	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	CH	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	IT	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	GB	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	EP	2803734	20.09.2017	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	DE	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	ES	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	FR	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	GB	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	IT	1 869 215	07.05.2014	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	US	8,129,107	06.03.2012	[redacted]
IMPROVED BISULFITE CONVERSION OF DNA	Epigenomics AG	US	8,586,302	19.11.2013	[redacted]
Method for quantification of methylated DNA	Epigenomics AG	US	8,703,414	22.04.2014	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	AT	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	AU	2005293703	03.06.2010	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	BE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	CA	2,581,500	12.02.2013	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment	Epigenomics AG	CH	1 659 186	21.05.2008	[redacted]

of nucleic acids					
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	DK	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	DE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	ES	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	FR	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	GB	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	IE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	IT	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	JP	4727670	22.04.2011	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	LU	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	NL	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	PT	1 659 186	21.05.2008	[redacted]

A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	SE	1 659 186	21.05.2008	[redacted]
A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids	Epigenomics AG	TR	1 659 186	21.05.2008	[redacted]
METHOD FOR THE DETERMINATION OF THE DNA METHYLATION LEVEL OF A CPG POSITION IN IDENTICAL CELLS WITHIN A TISSUE SAMPLE	Epigenomics AG	US	8,912,129	16.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	AE	933/2007	17.04.2006	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	AU	2006236620	08.06.2012	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	BR	PI0607508-8	12.01.2021	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CA	2,606,296	21.05.2019	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	ZL200680012490.0	14.05.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	ZL201410147754.X	28.07.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HK	HK1202137	22.06.2018	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	ZL 2017 1 0510986.0	18.03.2022	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HK	HK1250521	23.12.2022	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CN	202210279361.9	17.04.2006	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	RU	13634	30.06.2010	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	EG	1102/2007	17.04.2006	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ES	2 045 335	31.12.2014	[redacted]

Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	FR	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CH	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	DE	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	GB	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IT	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	EP	2 045 335	31.12.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HK	HK1118868	18.02.2015	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ID	P000038296	17.04.2015	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IL	186556	29.08.2014	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IN	248746	19.08.2011	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	JP	5341506	16.08.2013	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	JP	5808306	18.09.2015	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	KR	10-1708544	14.02.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	MX	290670	03.10.2011	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	PH	1-2007-502117	06.01.2012	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SG	183708	14.08.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	7,951,563	31.05.2011	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	8,900,829	02.12.2014	[redacted]

Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ZA	2007/08701	26.11.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	AT	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	BE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CH	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	CZ	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	DK	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	EP	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	DE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	ES	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	FI	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	FR	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	GB	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	GR	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	HU	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	IT	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	LU	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	NL	1 721 992	08.10.2008	[redacted]

Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	PL	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	PT	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SE	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SI	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	SK	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	TR	1 721 992	08.10.2008	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	7,749,702	06.07.2010	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	9,695,478	04.07.2017	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	10,385,402	20.08.2019	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	11,186,879	30.11.2021	[redacted]
Methods and nucleic acids for analyses of cellular proliferative disorders	Epigenomics AG	US	17/512,833	17.04.2006	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	AU	2006236363	14.02.2013	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	CA	2,603,815	26.09.2017	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	EP	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	AT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	BE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	BG	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	CH	1 871 912	29.02.2012	[redacted]

Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	CY	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	CZ	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	DE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	DK	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	EE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	ES	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	FI	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	FR	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	GB	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	GR	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	HU	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	IE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	IS	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	IT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	LT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	LU	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	LV	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	MC	1 871 912	29.02.2012	[redacted]

Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	NL	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	PL	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	PT	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	RO	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	SE	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	SI	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	SK	1 871 912	29.02.2012	[redacted]
Method For Determining DNA Methylation In Blood Or Urine Samples	Epigenomics AG	TR	1 871 912	29.02.2012	[redacted]
A Method For Providing DNAFragments Derived From A Remote Sample	Epigenomics AG	JP	5674696	09.01.2015	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	JP	5133238	16.11.2012	[redacted]
A Method For Providing DNA Fragments Derived From A Remote Sample	Epigenomics AG	US	10,731,215	04.08.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	AU	2007237444	05.09.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CA	2,649,777	14.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	EP	2 479 283	22.06.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	5323680	26.07.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS	Epigenomics AG	US	17/590,200	17.04.2007	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	CH	2 049 684	06.05.2015	[redacted]

A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	GB	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	DE	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	IT	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	ES	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	FR	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	EP	2 049 684	06.05.2015	[redacted]
A METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID	Epigenomics AG	US	8,771,939	08.07.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	EP	2044221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2 044 221	22.07.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	EP	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2 634 265	14.09.2016	[redacted]

METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2 634 265	14.09.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS	Epigenomics AG	US	16/143,085	23.07.2007	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	EP	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	IT	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	GB	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	FR	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	ES	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	DE	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analyses of cellular proliferative disorders	Epigenomics AG	CH	2 049 681	21.09.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	DE	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	ES	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	GB	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	FR	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	EP	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	CH	2 099 938	16.11.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	IT	2 099 938	16.11.2016	[redacted]

Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	JP	5562034	20.06.2014	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	JP	6017497	07.10.2016	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	US	9,605,306	28.03.2017	[redacted]
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders	Epigenomics AG	US	9,850,532	26.12.2017	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	CH	2 044 215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	EP	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	DE	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	ES	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	FR	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	GB	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	IT	2044215	25.03.2015	[redacted]
Methods and nucleic acids for analyses for cellular proliferative disorders	Epigenomics AG	US	9,939,441	10.04.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	AU	2008207110	30.01.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CA	2,675,895	22.03.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CA	2,921,557	08.02.2022	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	RU	018010	30.04.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2 258 871	14.05.2014	[redacted]

METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	BE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	SE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CZ	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GR	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	HR	P20140692	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	HU	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	EE	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DK	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FI	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	AT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	PL	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	MC	2 258 871	14.05.2014	[redacted]

METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	MT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IS	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	NL	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	NO	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	SI	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	SK	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	TR	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	LT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	LU	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	LV	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	PT	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	RO	2 258 871	14.05.2014	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	BG	2 258 871	14.05.2014	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	CH	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	DE	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	ES	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	FR	2 115 165	14.03.2012	[redacted]
Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	GB	2 115 165	14.03.2012	[redacted]

Methods And Nucleic Acids For Analyses Of Cell Proliferative Disorders	Epigenomics AG	IT	2 115 165	14.03.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IL	199894	01.03.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IL	233548	31.10.2015	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	5342456	16.08.2013	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	5818374	09.10.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	GB	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	FR	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	CH	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	DE	1 842 926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	ES	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	IT	1842926	19.08.2015	[redacted]
A method of identifying a biological sample for methylation analysis	Epigenomics AG	EP	1 842 926	19.08.2015	[redacted]
IMPROVED METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	WO	PCT/EP2022/072276	08.08.2022	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL	Epigenomics AG	ES	3078751	01.08.2018	[redacted]

PROLIFERATIVE DISORDERS					
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS	Epigenomics AG	EP	3078751	01.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSES OF LUNG CARCINOMA	Epigenomics AG	JP	5694776	13.02.2015	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	ES	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CH	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	GB	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	EP	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FI	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	GR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CY	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CZ	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SI	2 479 289	06.04.2016	[redacted]

METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SK	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	TR	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	RO	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HU	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IS	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LU	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LV	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	MC	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	MT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NL	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NO	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	PL	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	PT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	AT	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	BE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	BG	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	EE	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DK	2 479 289	06.04.2016	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HK	HK1172656	23.06.2017	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	GB	3101141	16.10.2019	[redacted]

METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	EP	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IT	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FR	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	CH	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	ES	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HK	1231931	04.12.2020	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HU	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	IS	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LT	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LU	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	LV	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	MC	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NL	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	NO	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	SI	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	FI	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	BE	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	DK	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION ANALYSIS	Epigenomics AG	HR	3101141	16.10.2019	[redacted]
METHOD FOR METHYLATION	Epigenomics AG	US	8,623,599	07.01.2014	[redacted]

ANALYSIS					
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	IT	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	GB	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	FR	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	ES	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	DE	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	CH	2966181	14.02.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR ANALYSIS OF BLADDER CELL PROLIFERATIVE DISORDERS	Epigenomics AG	JP	6013910	30.09.2016	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	CH	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	EP	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	DE	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	ES	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	FR	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	GB	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	IT	2 309 005	04.03.2015	[redacted]
Methods for preservation of genomic DNA sequence complexity	Epigenomics AG	US	9,624,530	18.04.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	AU	2012282528	28.07.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	BR	1120140004439	23.03.2021	[redacted]

METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	CA	2,840,149	26.10.2021	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	CN	201810020458.1	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	RU	034232	20.01.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IT	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	GB	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	FR	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	ES	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	DE	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	EP	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	CH	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	DK	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	FI	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	HR	P20180001	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	HU	2729579	04.10.2017	[redacted]

METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IE	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	AL	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IS	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	NL	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	NO	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	LT	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	LU	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	LV	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	MC	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	MK	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	SE	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	SI	2729579	04.10.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	ID	IPD000047814	14.09.2017	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IL	230303	01.09.2018	[redacted]

METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	IN	36/DELNP/2014	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	JP	6397762	07.09.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	KR	10-2046668	13.11.2019	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	MX	358117	06.08.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	HK	1197754	27.07.2018	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	PH	1-2014-500063	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	SG	196421	24.10.2016	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	US	10,626,462	21.04.2020	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	US	11,261,499	01.03.2022	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	US	17/577,836	09.07.2012	[redacted]
METHODS AND NUCLEIC ACIDS FOR DETERMINING THE PROGNOSIS OF A CANCER SUBJECT	Epigenomics AG	ZA	2014/00089	30.03.2022	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	CH	1 963 352	08.09.2010	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	CN	101331148	27.06.2012	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	DE	1 963 352	08.09.2010	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	FR	1 963 352	08.09.2010	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	GB	1 963 352	08.09.2010	[redacted]

NEW METHOD FOR BISULFITE TREATMENT	Epigenomics AG	JP	5374679	04.10.2013	[redacted]
NEW METHOD FOR BISULFITE TREATMENT	Hoffmann - La Roche, Inc.	US	8,137,937	20.03.2012	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	CN	ZL 201580068711.5	26.03.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IT	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	GB	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	FR	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	ES	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	DE	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	CH	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	EP	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	NL	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	NO	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	SE	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	SI	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	AL	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	DK	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	FI	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	HR	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR	Epigenomics AG	HU	3234184	20.03.2019	[redacted]

DIAGNOSING CANCER					[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IE	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IS	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	LT	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	LU	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	LV	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	MC	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	MK	3234184	20.03.2019	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	HK	1245845	24.04.2020	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	IT	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	GB	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	FR	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	ES	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	CH	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	DE	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	EP	3540075	28.07.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	HK	HK40014441	14.04.2022	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	JP	6731942	09.07.2020	[redacted]
METHODS FOR DETECTING CpG	Epigenomics AG	US	9,957,575	01.05.2018	[redacted]

METHYLATION AND FOR DIAGNOSING CANCER					
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	US	11,345,966	31.05.2022	[redacted]
METHODS FOR DETECTING CpG METHYLATION AND FOR DIAGNOSING CANCER	Epigenomics AG	US	17/730,100	18.12.2015	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	CN	201780009085.1	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	JP	7261587	12.04.2023	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	JP	2022-211507	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	US	16/072,792	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	EP	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HK	42021042786.0	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	IT	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	EP	20214665.0	27.01.2017	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	CH	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	DE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	ES	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	FR	3408407	06.01.2021	[redacted]

METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	GB	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	MT	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	FI	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	AL	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	DK	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HR	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HU	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	IE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	IS	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	LT	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	LU	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	LV	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	MC	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	MK	3408407	06.01.2021	[redacted]

METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	NL	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	SE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	SI	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	BE	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	NO	3408407	06.01.2021	[redacted]
METHODS FOR DETECTING CpG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES	Epigenomics AG	HK	HK40000100	15.10.2021	[redacted]
METHODS FOR DETECTING HEAD AND NECK CANCER	Epigenomics AG	CN	202080028396.4	13.02.2020	[redacted]
METHYLATED GENOMIC DNA AS A MARKER OF HEAD AND NECK CANCER	Epigenomics AG	HK	62022054573.0	13.02.2020	[redacted]
METHYLATED GENOMIC DNA AS A MARKER OF HEAD AND NECK CANCER	Epigenomics AG	EP	20704032.0	13.02.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	AU	2020406068	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	CA	3,161,720	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	CN	202080095046.X	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	EP	20829901.6	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	JP	JP2022-536776	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	MX	MX/a/2022/007434	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	US	17/785,302	16.12.2020	[redacted]
METHODS FOR DETECTING COLORECTAL CANCER	Epigenomics AG	WO	PCT/EP2020/086498	16.12.2020	[redacted]
METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	EP	21742157.7	21.07.2021	[redacted]
METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	JP	JP2023-504199	21.07.2021	[redacted]

METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	US	18/015,912	21.07.2021	[redacted]
METHODS FOR DETECTING LIVER CANCER	Epigenomics AG	WO	PCT/EP2021/070362	21.07.2021	[redacted]
IMPROVED METHODS FOR DETECTING CANCER FIELD OF THE INVENTION	Epigenomics AG	EP	22199681.2	04.10.2022	[redacted]
MULTI-ANALYTE DIAGNOSTIC AND PROGNOSTIC ASSAYS FOR COLORECTAL CANCER AND USES THEREOF	Epigenomics AG	US	63/381,706	31.10.2022	[redacted]
MULTI-ANALYTE DIAGNOSTIC AND PROGNOSTIC ASSAYS FOR COLORECTAL CANCER AND USES THEREOF	Epigenomics AG	US	63/413,043	04.10.2022	[redacted]

Trademarks

Country	Trademark Application Number /Registration Number	Mark	Status	Owner
DE	304 59 611	HeavyMethyl	Registered	Epigenomics AG
GB	UK00800888748	HeavyMethyl	Registered	Epigenomics AG
CN	200612567	HeavyMethyl	Registered	Epigenomics AG
WO	0 888 748	HeavyMethyl	Registered	Epigenomics AG
EM	0888748	HeavyMethyl	Registered	Epigenomics AG
AR	2906270	Epi proColon	Registered	Epigenomics AG
BR	907685650	Epi proColon	Registered	Epigenomics AG
BR	907685331	Epi proColon	Registered	Epigenomics AG
BR	907685722	Epi proColon	Registered	Epigenomics AG
CN	13532351	Epi proColon	Registered	Epigenomics AG
CL	1183742	Epi proColon	Registered	Epigenomics AG
CL	1164785	Epi proColon	Registered	Epigenomics AG
CN	13532350	Epi proColon	Registered	Epigenomics AG
CN	13532352	Epi proColon	Registered	Epigenomics AG
CL	1175380	Epi proColon	Registered	Epigenomics AG
RU	564091	Epi proColon	Registered	Epigenomics AG
AR	2820458	Epi proColon	Registered	Epigenomics AG
AR	2820457	Epi proColon	Registered	Epigenomics AG
DE	30 2009 031 560	Epi proColon	Registered	Epigenomics AG
EM	008 703 654	Epi proColon	Registered	Epigenomics AG
GB	UK00908703654	Epi proColon	Registered	Epigenomics AG
US	4,235,996	Epi proColon	Registered	Epigenomics AG
CN	13532349	Epi proLung	Registered	Epigenomics AG
CN	13532347	Epi proLung	Registered	Epigenomics AG
CN	13532348	Epi proLung	Registered	Epigenomics AG
DE	30 2009 031 561	Epi proLung	Registered	Epigenomics AG
EM	008 703 671	Epi proLung	Registered	Epigenomics AG
GB	UK00908703671	Epi proLung	Registered	Epigenomics AG
DE	30 2009 031 562	Epi proProstate	Registered	Epigenomics AG
EM	008 703 662	Epi proProstate	Registered	Epigenomics AG
GB	UK00908703662	Epi proProstate	Registered	Epigenomics AG
EM	008 794 505	Epi proBladder	Registered	Epigenomics AG
GB	UK00908794505	Epi proBladder	Registered	Epigenomics AG
DE	30 2009 039 312	Epi proBreast	Registered	Epigenomics AG
EM	008 794 521	Epi proBreast	Registered	Epigenomics AG
GB	UK00908794521	Epi proBreast	Registered	Epigenomics AG

DE	30 2010 002 554	Epi proCervix	Registered	Epigenomics AG
EM	009 234 477	Epi proCervix	Registered	Epigenomics AG
GB	UK00909234477	Epi proCervix	Registered	Epigenomics AG
EM	017950053	HCCBloodTest (Bildmarke)	Registered	Epigenomics AG
US	5,935,705	HCCBloodTest	Registered	Epigenomics AG
GB	UK00917950053	HCCBloodTest (Bildmarke)	Registered	Epigenomics AG
US	6,126,563	HCCBloodTest	Registered	Epigenomics AG

SCHEDULE 11(l)

1. Assignment of Patent Rights dated as of July 17, 2023, by and between Seller and Epigenomics Inc.

2. IP Transfer Agreement dated as of July 17, 2023, by and between Seller and Epigenomics Inc.

3. Service Agreement dated as of December 13, 2021, by and between Jens Ravens and Seller.

4. Backstop Agreement dated as of June 11, 2021, last amended on August 20, 2021, by and between Seller and Deutsche Balaton Aktiengesellschaft.

5. Loan Agreement dated as of April 1, 2021, by and between Seller and Epigenomics Inc.

6. Loan Agreement dated as of April 1, 2022, by and between Seller and Epigenomics Inc.

7. Transfer Pricing Agreement dated as of September 21, 2015, by and between Seller and Epigenomics Inc.